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ARTICLE
Enveloped viruses distinct from HBV induce
dissemination of hepatitis D virus in vivo
Jimena Perez-Vargas 1, Fouzia Amirache1, Bertrand Boson1, Chloé Mialon1, Natalia Freitas1, Camille Sureau2,
Floriane Fusil1 & François-Loïc Cosset 1
Hepatitis D virus (HDV) doesn’t encode envelope proteins for packaging of its ribonucleo-
protein (RNP) and typically relies on the surface glycoproteins (GPs) from hepatitis B virus
(HBV) for virion assembly, envelopment and cellular transmission. HDV RNA genome can
efﬁciently replicate in different tissues and species, raising the possibility that it evolved, and/
or is still able to transmit, independently of HBV. Here we show that alternative, HBV-
unrelated viruses can act as helper viruses for HDV. In vitro, envelope GPs from several virus
genera, including vesiculovirus, ﬂavivirus and hepacivirus, can package HDV RNPs, allowing
efﬁcient egress of HDV particles in the extracellular milieu of co-infected cells and sub-
sequent entry into cells expressing the relevant receptors. Furthermore, HCV can propagate
HDV infection in the liver of co-infected humanized mice for several months. Further work is
necessary to evaluate whether HDV is currently transmitted by HBV-unrelated viruses in
humans.
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Hepatitis D virus (HDV) was discovered 40 years ago in theliver of individuals chronically infected with hepatitis Bvirus (HBV), a liver-speciﬁc pathogen present in ca. 250
million people. The HDV virion released in the extracellular
milieu is an enveloped particle with an average diameter of
36 nm. It consists of a cell-derived lipid envelope harboring
HBV surface proteins and coating an inner ribonucleoprotein
(RNP)1–4, which is composed of a multimer of ca. 70 copies of the
HDV-encoded delta antigen (HDAg) protein5,6 that is associated
to one copy of the small circular single-strand HDV RNA exhi-
biting self-annealing properties, conferring its rod-like
conformation6,7. Although HDAg was initially considered as a
novel HBV antigen8, it was later shown to be associated with a
small RNA as a transmissible and defective agent that uses the
HBV envelope glycoproteins (GP) for its propagation, hence
reﬂecting its nature of an obligate satellite of HBV. Indeed, HDV
particles appear not to require speciﬁc cellular functions to pro-
mote egress of its RNP and to only rely on the budding
mechanism provided by HBV envelope GPs, which hence offers
the exclusive HBV contribution to the HDV life cycle. Their
ensuing envelopment subsequently allows targeting and entry of
HDV particles to human hepatocytes via mechanisms that
depend on the same host entry factors than those used by HBV
itself, i.e., through low-afﬁnity attachment to cell surface heparan
sulfate proteoglycans (HSPGs)9,10 and subsequent high-afﬁnity
engagement to the sodium taurocholate cotransporting poly-
peptide (NTCP)11,12.
Noteworthy, the origin of HDV is currently unknown. The
characterization of the HDAg-associated RNA, the HDV genome,
revealed that it is unique among animal viruses and that it shares
some properties with some plant agents called viroids13,14.
Indeed, the replication of its RNA involves the HDAg-mediated
subversion of cellular RNA polymerase(s), such as Pol-II. Both
genomic HDV RNA and antigenomic RNA (its replication
intermediate) strands include ribozyme autocatalytic, self-
cleaving elements. Interestingly, cells from highly divergent
organisms express several HDV-like cellular ribozymes that play
a role in many biological pathways15,16. This has raised the
possibility that HDV RNA originated from the cell transcriptome
itself, in agreement with the ﬁnding that circular RNA species are
abundant in cells17. Therefore, one possibility could be that the
HDV RNA has emerged in HBV-infected hepatocytes subsequent
to evolution of cellular circular RNA forms becoming autono-
mously replicative18 and for which the ribozyme and HDAg-
coding RNA sequences may have arisen from the human
transcriptome19,20. Accordingly, that HBV, a strictly liver-tropic
human pathogen, only provides RNP envelopment and trans-
mission functions would therefore explain why HDV has been
exclusively detected in the liver of HBV-infected patients. Alter-
natively, that HDV RNA can self-replicate in a much wider
variety of cell types and species21–23 raises the theoretical possi-
bility that it may be transmitted through unorthodox means.
Furthermore, viruses closely related to HDV have been detected
in non-human species in the absence of any hepadnavirus24,25.
Also, primary Sjögren’s syndrome patients were reported to
present HDV antigen and RNA in salivary glands in the absence
of HBsAg or HBV antibodies26.
Here, aiming to explore scenarios concerning the origin of
HDV, we investigate the possibility that other, HBV-unrelated
viruses could provide helper envelopment, budding, and entry
functions. Our results indicate that HDV RNPs may exploit
assembly functions provided by viruses from several alternative
genera and families, including vesiculovirus, ﬂavivirus, and
hepacivirus, among other enveloped viruses. This compatibility
allows efﬁcient egress in the extracellular milieu of co-infected
cells of HDV particles that appear to be infectious. This leads to
their subsequent entry into different cell types expressing the
receptors targeted by the GPs of either virus genus and dis-
semination of HDV genome in vivo in experimentally infected
humanized mice.
Results
HDV particle assembly with vesiculovirus and hepacivirus GPs.
HDV particles were produced in Huh-7 cells by co-transfecting
two plasmids, a ﬁrst one providing the envelope GPs from HBV
vs. alternative enveloped viruses, i.e., vesicular stomatitis virus
(VSV) G protein and hepatitis C virus (HCV) E1E2 proteins, and
a second one initiating the replication of the HDV RNA genome
(pSVLD327) that encodes the HDV delta protein (HDAg). As
controls, we co-transfected with pSVLD3 an “empty” plasmid
that does not encode GPs (“No GP”) for assessing speciﬁc pro-
duction, release, and infectivity of HDV particles. At 3, 6, and
9 days post transfection, the production of HDV particles was
determined by quantifying by RT-qPCR of the HDV RNAs from
the supernatants. While HDV RNAs accumulated at high levels
in producer cells for all transfection conditions, reﬂecting its self-
replication independently of GP expression, it was readily
detected in the cell supernatants when the HBV GPs were co-
expressed in transfected cells (Fig. 1a) with an over 4-log fold
increase after day 3, in agreement with previous reports28,29. In
contrast, no signiﬁcant HDV RNA secretion could be detected
over the RT-qPCR threshold levels when pSVLD3 was transfected
without GP (“No GP” control), conﬁrming that HDV RNA
release from cells requires co-expression of HBV GPs29.
Strikingly, we found that the release of HDV RNAs could also
be induced by envelope GPs from alternative viruses, as suggested
by progressively increased secretion of extracellular HDV RNAs
over time post transfection (Fig. 1a). Speciﬁcally, at day 9 post
transfection, we detected high levels of HDV RNA in the
supernatants of cells co-expressing these GPs and HDV RNAs, by
up to 109 GE/mL for VSV-G GP-expressing cells, i.e., ca. sixfold
higher than for HBV GPs, and by ca. 5 × 107 GE/mL for HCV-
E1E2 GP-transfected cells (Fig. 1a). We conﬁrmed that these
extracellular RT-qPCR signals reﬂected bona ﬁde HDV RNAs, as
shown by strand-speciﬁc RT-PCR experiments that detected
genomic HDV RNA at the expected size of 1.7 kb (Fig. 1b) and by
northern blot experiments performed on pellets of ultracentri-
fuged supernatants from producer cells that revealed full-length
HDV RNAs (Fig. 1c). Then, using a strand-speciﬁc RT-qPCR
assay30,31 that speciﬁcally quantiﬁes either genomic (gRNA) or
antigenomic (agRNA) HDV RNAs (Supplementary Fig. 1f), we
found a strong enrichment of HDV gRNA in the supernatants of
cells transfected by pSVLD3 and either of these GP expression
plasmids, as compared with lysates of producer cells (Supple-
mentary Fig. 1a–c). The HDV gRNAs accounted for over 99% of
HDV RNAs detected in the supernatants of these cells
(Supplementary Fig. 1d–e), suggesting that VSV and HCV GPs
induced extracellular release of genomic HDV RNA in a manner
similar to HBV GPs.
Next, we sought to investigate the biochemical form of these
extracellular genomic HDV RNAs. As shown in Fig. 1e, we found
that immunoprecipitation of producer cell supernatants with
antibodies against HBV, VSV, or HCV GPs could co-precipitate
HDV RNAs in a GP-speciﬁc manner, which suggested that the
latter are in the form of GP-associated RNPs. In agreement with
this possibility, when we immunoblotted the pellets of ultra-
centrifuged producer cell supernatants with HDAg antibodies
(Fig. 1d), we found similar levels and ratios of L- and S-HDAg for
particles generated with HCV and VSV GPs as compared with
“normal” HDV particles produced with HBV GPs. This suggested
that the detected genomic HDV RNAs (Fig. 1a–c) are
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incorporated as RNPs exhibiting wild-type properties. Of note,
co-expression of HDV RNPs with HCV and VSV GPs did not
induce higher cytotoxicity levels than those detected in cells
producing “normal” HDV particles or in non-transfected cells
(Supplementary Fig. 2), suggesting genuine processes of envelop-
ment and production of these novel HDV particles. Altogether,
these results indicated that HDV can be enveloped by different
types of viral surface glycoproteins, which induces secretion of
HDV RNPs in the extracellular milieu.
To further characterize the non-HBV-induced HDV particles
(Δp) coated with VSV-G or HCV-E1E2 envelope GPs, hereafter
designated VSV-Δp and HCV-Δp, we incubated the supernatants
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of Δp-producer cells with heparin-coated beads and we examined
the eluted material by electron microscopy. We observed two
types of spheres with diameters of 35–40 and 25–30 nm (Fig. 1f).
The small spheres likely corresponded to subviral particles since
they were also detected when VSV-G and HCV-E1E2 were
expressed alone, similar to HBV GPs (Supplementary Fig. 3c, 3d),
whereas the large spheres, that were only detected when HDV
RNA were transcribed along with either co-expressed GP
(Supplementary Fig. 3a, 3b), could correspond to VSV-Δp and
HCV-Δp particles. Next, the supernatants of Δp-producer cells
were subjected to equilibrium centrifugation on preformed
iodixanol density gradients. Fractions collected from the gradients
were assayed for density and HDV RNA by RT-qPCR (Fig. 1g).
We found that HDV particles assembled with HBV GPs (noted
“HDV” in the ﬁgures) exhibited a major peak of HDV RNAs at
1.12–1.14 g/mL, whereas HDV RNAs were detected at lower
densities of 1.07–1.10 for VSV-Δp and of 1.08–1–13 for HCV-Δp
(Fig. 1g). Finally, we found that these secreted HDV RNAs were
genomic RNAs, as shown by strand-speciﬁc RT-PCR-binding
assays (Fig. 1g, below density graphs). Altogether, these results
indicated that heterologous envelope GPs can induce assembly of
HDV particles, which are homogeneous and peak at densities
likely reﬂecting the physicochemical features of the combination
of HDV RNPs with these envelope GPs of different natures.
HDV assembled with heterologous envelope GPs is infectious.
To determine whether the HDV particles produced with VSV-G
or HCV-E1E2 envelope GPs were infectious, we performed
infection assays using HDV replication-permissive Huh-106,
Huh-7, and 293T cells that express different sets of virus entry
receptors. At 7 days post inoculation, i.e., corresponding to the
plateau of HDV RNA replication29,32 (see below), the levels of
infected cells and intracellular HDV RNAs were measured by
counting HDAg-positive focus-forming units (FFU) via HDAg
immunoﬂuorescence (Fig. 2b, c) and by RT-qPCR (Fig. 2a),
respectively. We found that the HDV particles produced with
HBV envelope GPs could readily induce HDV RNA replication in
inoculated Huh-106 cells expressing the HBV receptor, NTCP,
but neither in Huh-7 nor in 293T cells, that are NTCP-negative,
over the experimental thresholds provided by the “No GP”
conditions, in agreement with previous studies12,33. Importantly,
we found that the VSV-Δp and HCV-Δp particles were infectious
(Fig. 2a–c). First, through RT-qPCR detection of HDV RNA in
inoculated cells, we found that VSV-Δp could readily induce
HDV RNA replication in the three cell types that all express the
VSV-G receptor, LDLr34,35, whereas HCV-Δp could efﬁciently
infect Huh-106 and Huh-7 cells but less efﬁciently 293T cells
(Fig. 2a), in line with the differential expression of HCV receptors
in either cell type36. Second, by using limiting dilution assays
through immunoﬂuorescence detection of HDAg (Fig. 2b), which
indicated translation of HDV RNAs in inoculated cells, we con-
ﬁrmed that the levels of infectivity detected for the VSV-Δp and
HCV-Δp particles were comparable to those of HBV GP-coated
HDV particles. We deduced that all three particles type had
similar speciﬁc infectivity, which is deﬁned here by the ratio
between the number of infectious viruses (measured in FFUs) and
the amounts of viral RNA-containing particles (determined by
RT-qPCR), with one infectious particle per 4000–7000 physical
particles (Fig. 2d).
Next, to demonstrate that HDV RNA was transmitted by a
bona ﬁde HDV infectious process, we incubated producer cells
with Lonafarnib, an inhibitor of prenylation that prevents HDV
assembly37,38, which requires RNP targeting to the ER membrane
by farnesylation of L-HDAg38. We found that Lonafarnib could
readily inhibit production of HBV GP-coated HDV, VSV-Δp,
and HCV-Δp particles (Fig. 3a) and hence, transmission and
replication of HDV RNA in inoculated cells (Fig. 3b). These
results indicated that farnesyl-mediated targeting to ER or other
cell membranes is required for assembly of VSV-Δp and HCV-Δp
particles, suggesting that they share with HDV the same early
steps, leading to production of infectious particles. Through time-
course analysis, we found that cells inoculated with VSV-Δp and
HCV-Δp particles accumulated over time post infection both
gRNA and agRNA (Fig. 3c), which indicated that HDV RNAs
could be ampliﬁed in a typical manner following entry into cells.
We show that this correlated with accumulation of genomic-size
HDV RNA (Fig. 3d) as well as of S-HDAg and L-HDAg proteins
(Fig. 3e) at similar levels and/or ratios than for HBV GP-coated
HDV particles, which indicated that full-sized HDV genomes
were replicated and translated in infected cells. Altogether, these
results demonstrated that HDV particles coated with the envelope
GPs of VSV and HCV induce functional entry into cells and,
hence, are infectious.
Then, to establish if VSV-Δp and HCV-Δp enter in the cells
through the same pathways as for the parental viruses (VSV and
HCV), particles were pre-incubated with antibodies that are
known to neutralize VSV and HCV before their inoculation onto
Huh-106 cells. The results in Fig. 4a show that the Hs33 antibody
targeting the HBsAg protein readily neutralized HDV particles
bearing HBV GPs but not HDV particles bearing the other GPs.
Conversely, the 41A1 antibody that blocks the entry of VSV36
neutralized VSV-Δp, whereas the AR3A antibody that neutralizes
HCV39 could only prevent infection of HCV-Δp particles. Then,
we sought to block the cell receptors used by either parental virus
with speciﬁc inhibitors (Fig. 4b). We found that while taurocholic
Fig. 1 Secretion of HDV particles is induced by surface glycoproteins from varied enveloped viruses. Huh-7 cells were co-transfected with pSVLD3 plasmid
coding for HDV RNPs and plasmids coding for HBV, VSV, or HCV surface glycoproteins (GP), resulting in “HDV”, “VSV-Δp”, and “HCV-Δp” samples,
respectively. As control, pSVLD3 was co-transfected with an empty plasmid (“No GP” samples). a At day 3, 6, or 9, extracellular HDV RNAs were
quantiﬁed from cell supernatants by RT-qPCR. Intracellular HDV RNAs were quantiﬁed from cell lysates at day 9 post transfection. HDV RNA levels in GE
(genome equivalent) are expressed as means (n= 5 independent experiments) per ml of cell supernatants for extracellular RNAs or, for intracellular RNAs,
per mL of cell lysates containing 106 cells. b RNAs extracted from lysates and supernatants of transfected cells treated with RNAse-free DNAse, or not
treated (–DNAse), were reverse-transcribed using a antigenomic primer that detects HDV RNAs and then PCR-ampliﬁed with HDV-speciﬁc primers to
reveal unit-length HDV genomic RNAs. As control, reverse transcriptase was omitted during processing of the samples (–RT). c, d In total, 2 × 107 HDV
GEs from pellets retrieved after ultracentrifugation of cell supernatants on 30% sucrose cushions were analyzed by northern blot using a HDV-speciﬁc
probe (c) or by western blot using an HDAg antibody (d). Control HDV RNAs (5 × 107 GE) (c) or HDAg from cell lysates (d) were loaded on the same gels
(Ctrl). e Pelleted cell supernatants containing 109 HDV GEs (“Input”) immunoprecipitated with antibodies against HBsAg (Hs33 mAb), VSV-G (41A1
mAb), and HCV-E1E2 (AR3A mAb) glycoproteins, as indicated, were quantiﬁed by RT-qPCR after elution. The results are expressed as percentages of
input values. f Electron microscopy of heparin bead-puriﬁed supernatants after elution and negative staining showing large (white arrows) and small (black
arrows) particles. Scale bar: 100 nm. g HDV RNAs, from fractions from cell supernatant samples separated on equilibrium-density gradients, were analyzed
by RT-qPCR, expressed as percentages of total HDV RNA contents, or by strand-speciﬁc RT-PCR that reveals HDV genome size (below each graph).
Source data are provided as a Source Data ﬁle. Error bars correspond to standard deviation. Statistical analyses (Student’s t-test): p < 0.05 (*)
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acid (TCA) speciﬁcally inhibited infection of Huh-106 cells with
HDV particles produced with HBV GPs, as expected12, antibodies
against LDLr and CD81 (i.e., one of the HCV receptors) blocked
the entry of VSV-Δp and HCV-Δp particles, respectively, though
LDLr antibodies exhibited some nonspeciﬁc levels of inhibition.
Altogether, the results of virus-neutralization and receptor-
blocking assays indicated that the conformation of the surface
of VSV-Δp and HCV-Δp particles is similar to that of parental
viruses and able to mediate GP-speciﬁc cell entry through their
corresponding receptors.
Thereafter, we explored if HDV particles could be produced
with envelope GPs from a broader set of enveloped viruses.
Hence, we co-transfected pSVLD3 with plasmids encoding the
GPs from RD114 cat endogenous virus, murine leukemia virus
(MLV), human immunodeﬁciency virus (HIV), avian inﬂuenza
virus (AIV), lymphocytic choriomeningitis virus (LCMV), human
metapneumovirus (HMPV), dengue virus (DENV), and West
Nile virus (WNV), which did not prevent HDV RNA replication
(Fig. 5a). We detected the secretion of HDV particles induced by
the GPs from HMPV, DENV, and WNV at levels similar to those
of HBV GPs and at lower levels with the GPs from LCMV,
though not with the GPs from the other viruses (Fig. 5b).
Importantly, while no infectivity could be detected in the
supernatants from the latter GPs, HDV particles enveloped with
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Fig. 2 HDV particles generated with heterologous envelope glycoproteins are infectious. a The infectivity of virus particles produced with HBV (HDV), VSV
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inoculums. The results show the ratios of HDAg-positive FFU induced by HDV RNA from the same inoculums. Source data are provided as a Source Data
ﬁle. Error bars correspond to standard deviation. Statistical analyses (Student’s t-test): p < 0.05 (*); p < 0.01 (**)
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Fig. 3 HDV, VSV-Δp, and HCV-Δp particles share an early step of assembly and induce identical HDV markers in infected cells. Huh-7 cells were co-
transfected with pSVLD3 plasmid coding for HDV RNPs and plasmids coding for HBV (HDV), VSV (VSV-Δp), or HCV (HCV-Δp) envelope glycoproteins.
As control, pSVLD3 was transfected without envelope proteins (No GP). a The transfected cells were grown in the presence (or not) of 1 mM Lonafarnib
(+L), a farnesyltransferase inhibitor, until collecting at day 6 or 9 post transfection (D6 vs. D6+ L and D9 vs. D9+ L) the cell supernatants, which were
ﬁltered and inoculated to Huh-106 cells. The RNAs from producer cells and supernatants were extracted and the HDV genomes (gRNAs) were quantiﬁed
by a strand-speciﬁc RT-qPCR assay. The quantiﬁcation of intracellular HDV RNAs in cells producing the HDV particles at day 9 post transfection is also
shown. HDV RNA levels in GE (genome equivalent) are expressed as means (n= 2 independent experiments) per ml of cell supernatants for extracellular
RNAs or, for intracellular RNAs, per ml of cell lysates containing 106 cells. b The inoculated cells were grown for 7 days before total intracellular RNA was
puriﬁed. The results of HDV gRNA quantiﬁcation by RT-qPCR are expressed as means (n= 2 independent experiments) per ml of cell lysates containing
106 cells. c–e Huh-106 cells inoculated with the indicated viral particles were harvested at different time points post infection. The RNAs were then
extracted from the lysed cells. The HDV RNAs were quantiﬁed by genomic (gRNA) (upper panel) or antigenomic (agRNA) (lower panel) strand-speciﬁc
RT-qPCR assays and are expressed as means (n= 4 independent experiments) GE per ml of cell lysates containing 106 cells (c). The results of a northern
blot experiment using 3 µg of total cellular RNA per well that were revealed with a HDV-speciﬁc probe (d). Intracellular proteins were extracted and
analyzed by western blot using an HDAg antibody (e). Control HDV RNAs (5 × 107 GE) (d) or HDAg from cell lysates (e) were loaded on the same gels
(Ctrl). Source data are provided as a Source Data ﬁle. Error bars correspond to standard deviation. Statistical analyses (Student’s t-test): p < 0.05 (*); p <
0.01 (**)
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the former GPs were infectious. They exhibited high infectivity
for those enveloped with DENV GPs (Fig. 5c), similar to HBV,
VSV-G, and HCV GPs (Fig. 2), but intermediate or lower
infectivity for particles assembled with LCMV, HMPV, and
WNV.
Finally, to extend these ﬁndings, we determined if HDV
particles could be produced from non-liver cells. Hence, the
pSVLD3 plasmid was co-transfected with members of the above
set of GP-expression plasmids in 293T human kidney cells.
Similar to production in Huh-7 cells, we found that HDV RNA
could replicate in 293T cells, and that infectious HDV particles
could be efﬁciently assembled and secreted with the HBV, VSV,
HCV, DENV, WNV, and HMPV GPs (Supplementary Fig. 4),
indicating that assembly and release of functional HDV with
heterologous GP is not cell-type restricted.
HDV coinfection with HCV or DENV rescues infectious HDV.
Next, to validate and extend the results of expression assays to a
more relevant infectious context, we sought to determine if HCV-
Δp and DENV-Δp particles could be produced after inoculation
of live HCV or DENV to cells expressing intracellular HDV
RNPs. Hence, we inoculated Huh-7.5 cells producing HDV RNAs
with either cell culture-grown HCV (HCVcc) or DENV at two
different MOIs, which were set at suboptimal values in order to
prevent virus-induced cell death. As control, we performed HBV
infection assays in Huh-106 cells producing HDV12,33.
At 5 days post inoculation with HCV, we detected intracellular
HCV-NS5A and HDAg in ca. 5–10% of co-infected cells
(Supplementary Fig. 5a). HCV and HDV RNAs were then
quantiﬁed by RT-qPCR from cell lysates and supernatants. As
shown in Fig. 6a, we could readily detect intracellular HCV RNAs
in cells replicating or not HDV RNA. Identical levels of
intracellular HDV RNAs of genomic size were detected in
HDV-expressing cells inoculated or not with HCV (Fig. 6a).
Likewise, HCV RNAs were detected in supernatants of these cells
at levels that were not affected by the presence of intracellular
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Fig. 4 Speciﬁc glycoprotein-receptor interactions mediate cell entry of HDV particles. a Similar inputs of virus particles produced with HBV (HDV), VSV
(VSV-Δp), or HCV (HCV-Δp) glycoproteins were incubated for 1 h at 37 °C with 100 ng/mL of neutralizing monoclonal antibodies against HBV HBsAg
(Hs33 mAb), VSV-G (41A1 mAb,) and HCV-E1E2 (AR3A mAb) glycoproteins vs. no antibody (mock) before infection of Huh-106 cells. b Similar inputs of
virus particles were used to infect Huh-106 cells that were pre-incubated for 1 h with compounds that block NTCP (TCA, taurocholic acid), LDLr (C7 mAb),
and CD81 (JS-81 mAb) vs. no antibody (mock). Infected cells were grown for 7 days before total intracellular RNA was puriﬁed. The results of HDV RNA
quantiﬁcation by RT-qPCR are expressed as means (n= 2 independent experiments) per mL of cell lysates containing 106 cells. Source data are provided as
a Source Data ﬁle. Error bars correspond to standard deviation. Statistical analyses (Student’s t-test): p < 0.05 (*); p < 0.01 (**)
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HDV RNA (Fig. 6b). Notably, we found that extracellular HDV
RNAs could be readily detected only in the supernatants from
cells co-infected with HDV and HCV (Fig. 6b), indicating that
HCV infection can provide helper functions for assembly and
secretion of HDV particles. These particles incorporated full-sized
genomic HDV RNA, as shown by strand-speciﬁc RT-PCR assays
(Fig. 6b, below the graphs). Next, we determined the infectivity of
virus particles by measuring intracellular HCV and HDV RNAs
in Huh-7.5 target cells 7 days after their inoculation with the
producer cell supernatants. We detected HCV RNAs in these
target cells, reﬂecting the presence of infectious HCV particles in
the supernatants of HCV-(co)infected cells, at similar levels
whether or not HDV genome was co-expressed in the producer
cells. Importantly, we found that the HDV particles produced
from HCV/HDV co-infected cells were infectious (Fig. 6c), as we
could readily detect HDV RNAs in these target cells well over the
experimental threshold provided by the control conditions.
Corroborating these results, cells that were co-infected by both
HCV and HDV or that were mono-infected by either virus were
observed by immunoﬂuorescence (Fig. 6d).
Noteworthy, the production and infectivity levels of HDV
particles produced by HCV/HDV co-infected cells were similar to
those of HDV particles produced with HBV as a co-infecting
helper virus (Fig. 6e–h). Overall, this indicated that infectious
HDV particles can be produced by coinfection with a non-HBV
helper virus. To further address this, since DENV GPs could also
provide helper functions for HDV RNP secretion (Fig. 5), we
investigated HDV propagation from DENV/HDV co-infected
Huh-7.5 cells (Fig. 6i; Supplementary Fig. 5a). We found that
DENV coinfection could induce the replication and secretion of
full-sized genomic HDV RNAs (Fig. 6i, j) at high levels,
equivalent to those obtained via DENV GP co-expression (Fig. 5).
This resulted in efﬁcient HDV and DENV infection levels in
Huh-7.5 target cells (Fig. 6k, l). Interestingly, similar results were
obtained when DENV/HDV particles were inoculated in C6/36
Aedes albopictus mosquito cells that are permissive to DENV
infection (Supplementary Fig. 6). We detected HDV (and DENV)
RNAs in DENV/HDV-infected C6/36 cells (Supplementary
Fig. 6d, 6e), which indicated entry and replication of HDV
RNA in insect cells, though at lower levels than for Huh-7.5 cells
(Supplementary Fig. 6a, 6b). Moreover, these DENV/HDV-
infected C6/36 cells allowed HDV RNP assembly, secretion, and
transmission to both Huh-7.5 and C6/36 naive cells (Supple-
mentary Fig. 6f, 6g).
Overall, these results indicated that infectious HDV particles
could be assembled in cells co-infected with different viruses
other than HBV, and that replication and infectivity of co-
infecting virus seem not affected by HDV replication.
HCV/HDV coinfection can disseminate in vivo. We then
sought to demonstrate that HCV could propagate HDV RNPs
in vivo. We generated cohorts of liver-humanized mice (HuHep-
mice) derived from the FRG mouse model40 (Fig. 7a). We
retained the animals that displayed >15 mg/mL of human serum
albumin (HSA), which corresponded to 40–70% of human
hepatocytes in the liver41. In agreement with previous
reports41,42, these animals supported HBV (Group#1) and HCV
(Group#5) infection for several months (Fig. 7b; see
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Fig. 5 Screening of surface glycoproteins from different enveloped viruses
that allow production of infectious HDV particles. Huh-7 cells were co-
transfected with pSVLD3 plasmid coding for HDV RNPs and plasmids
coding for HBV glycoproteins (designated “HDV”) or for surface
glycoproteins of the indicated enveloped viruses. The RD114TR GP is a
cytoplasmic tail-modiﬁed variant of the RD114 GP that allows its trafﬁcking
to late endosomal compartments54,55. As control, pSVLD3 was co-
transfected with an empty plasmid (referred to as “No GP”). a The
quantiﬁcation of intracellular HDV RNAs in lysates of cells at day 9 post
transfection is shown. HDV RNA levels in GE (genome equivalent) are
expressed as means (n= 2 independent experiments) per mL of cell lysates
containing 106 cells. b At day 9 post transfection, the cell supernatants
were harvested, ﬁltered, and the extracellular RNA was extracted and
puriﬁed before quantifying HDV RNAs by RT-qPCR. HDV RNA levels in GE
are expressed as means (n= 2 independent experiments) per mL of cell
supernatants. c Huh-106 cells were incubated with the above supernatants.
Infected cells were grown for 7 days before total intracellular RNA was
puriﬁed. The results of HDV RNA quantiﬁcation by RT-qPCR are expressed
as means (n= 2 independent experiments) per mL of cell lysates
containing 106 cells. The dotted lines represent the experimental
thresholds, as deﬁned with the “No GP” controls. Note that only
supernatants containing secreted HDV RNAs (b) allow infectivity of HDV
particles containing HBV (HDV), LCMV (LCMV-Δp), HPMV (HPMV-Δp),
DENV (DENV-Δp), or WNV (WNV-Δp) GPs (c). Source data are provided
as a Source Data ﬁle. Error bars correspond to standard deviation.
Statistical analyses (Student’s t-test): p < 0.05 (*); p < 0.01 (**)
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Supplementary Fig. 7a for individual mice). In contrast, inocu-
lation of HuHep-mice with “helper-free” HDV, i.e., HDV parti-
cles produced with HBV GP-expression plasmid (Fig. 1), did not
lead to HDV viremia, as shown by RT-qPCR values in infected
animal sera that were identical to those detected in the non-
infected HuHep-mice control group (Group#9: HDV vs.
Group#10: Mocks; Supplementary Fig. 7a). The other groups of
HuHep-mice (5–8 animals each) were inoculated with either
“helper-free” HDV followed by HCV 4 weeks later (Group#7),
HCV followed by “helper-free” HDV (Group#6), or both HCV
and “helper-free” HDV simultaneously (Group#8). HDV RNAs
were detected in animals of the three latter groups within a few
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weeks after inoculation. All HCV-positive animals of these groups
were also positive for HDV (Fig. 7b; Supplementary Fig. 7a) and
secreted HDV RNA of genomic size was detected in the sera (see
examples for two animals/group in Supplementary Fig. 7b). We
obtained qualitatively comparable results in HuHep-mice co-
infected with HDV and HBV (Fig. 7a, b, Group#2, #3, and #4;
Supplementary Fig. 7a, 7b). Of note, similar results were obtained
in another cohort of HuHep-mice in which HDV was inoculated
1 week after HCV (Supplementary Fig. 8). Altogether, these
results indicated that HDV can be propagated in vivo by different
virus types, including HCV.
Discussion
Satellite viruses are scarcely found in animal viruses in contrast to
their profusion in plant viruses. Only two representative satellite
viruses are known currently in human viruses and include HDV
and adeno-associated virus (AAV), which uses helper functions of
e.g., adenovirus or herpes simplex virus at the level of replication
of its genome, unlike for HDV. Indeed, HDV has been described
as a satellite virus of HBV, a liver-speciﬁc human pathogen that
provides its surface GPs to induce envelopment and secretion of
HDV RNPs, as well as transmission to other cells via HBV cell
entry factors. In vivo, HDV has been found to be associated with
HBV in >5–10% of the ca. 250 million HBV-infected indivi-
duals43 worldwide.
A speciﬁc feature of HBV is the assembly and secretion of
different types of viral particles. While the three HBV envelope
GPs, S-HBsAg, M-HBsAg, and L-HBsAg, induce the secretion of
bona ﬁde virions incorporating HBV capsid and DNA genome
through the ESCRT assembly and budding machinery in cellular
multivesicular bodies (MVB)44,45, they also induce a particularly
abundant formation of HBV nucleocapsid-free subviral particles
(SVPs) at a pre-Golgi membrane that are subsequently exported
through the cell secretory pathway46. The latter type of particles is
exploited by HDV through a process allowing binding of its RNP
to a cytosolic determinant of the HBV envelope GPs29,38,47–49.
Hence, as HBV SVPs outnumber by ca. 4 orders of magnitude of
the HBV virions50, HDV RNPs are particularly efﬁciently coated
and secreted with the HBV envelope GPs, with titers that can
reach up to 1011 HDV virions per mL of serum, and are conse-
quently transmitted to the liver, which explains why HDV and
HBV share tropism to human hepatocytes.
Yet, genetically, HDV belongs to a group of infectious agents that
are related to plant viroids and that are completely distinct from
HBV. As HDV efﬁciently replicates in different tissues and spe-
cies23, here we raised the hypothesis that it may have arisen from
and/or conceivably still infects hosts independently of HBV. To
formally address this possibility, we questioned whether different
enveloped viruses, totally unrelated to HBV and HDV themselves,
could provide both assembly and entry functions to HDV particles.
By testing GPs from ten different virus genera, we demonstrate that
HDV RNPs could be enveloped by GPs from six of these non-HBV
particles and could produce infectious HDV particles.
The nature of the determinant(s) and mechanism(s) allowing
HDV assembly with these unconventional GPs remains to be
unraveled. Noteworthy, a farnesylation signal located at the C-
terminus of L-HDAg anchors the HDV RNP to the ER mem-
brane38, the site where, by deﬁnition, envelope GPs are generally
synthesized and translocated. Such early assembly events of HDV
production seem also to be used for assembly of HDV RNP with
alternative GPs, such as VSV-G and HCV-E1E2 GPs, since
inhibition of this pathway by Lonafarnib, a farnesyltransferase
inhibitor that is currently in phase-IIa clinical trial51, could
readily prevent production and transmission of HDV, VSV-Δp,
and HCV-Δp particles (Fig. 3). As for conventional HDV parti-
cles assembly, i.e., associated with HBV GPs, S-HBsAg is neces-
sary and sufﬁcient for assembly of HDV, although incorporation
of L-HBsAg is required for infectivity52. Previous studies have
described a crucial determinant of HDV envelopment, consisting
of a conserved tryptophan-rich motif present in the cytosolic side
of the S-HBsAg that acts as an HDV matrix domain and binds a
poorly conserved proline-rich C-terminal sequence located before
the farnesylation site of L-HDAg48. Yet, such a tryptophan-rich
motif is likely not present in the heterologous GPs that induce
efﬁcient HDV release, such as e.g., VSV-G, HCV-E1E2, and
DENV-PrME, inferring that a speciﬁc interaction between HDV
RNP and these envelope GPs is highly improbable. Rather, this
indicates that besides such speciﬁc HDV/HBV interaction
allowing HDV transmission and subsequent pathogenesis, other
determinant(s) of envelopment of HDV RNPs must exist.
How viruses in general exploit or subvert cellular envelopment
processes and machineries is of major interest. Budding
mechanisms vary widely for different virus families and there are
few common principles that govern these events. Particularly, the
assembly and budding of enveloped virus particles is a complex
and multistep process that involves the simultaneous recruitment
of viral proteins, surface GPs and inner structural proteins, and
nucleic acids to varying assembly sites. Such sites can be localized
either at the plasma membrane (e.g., HIV) or in the lumen of
diverse intracellular membranes (e.g., HCV, DENV), such as the
ER as well as the nuclear envelope, the intermediate or pre-Golgi
compartment, the Golgi cisternae and trans-Golgi network, and
the endosomes. Alternatively, assembly sites can be generated via
speciﬁc virus-induced membranous structures or compart-
ments53. Accordingly, a critical determinant of GP incorporation
in the envelopes of retrovirus particles allows intracellular traf-
ﬁcking of GP and colocalization with nucleocapsids, although
Fig. 6 HDV RNA-producing cells infected with HCV and DENV secrete infectious HDV particles. Huh-7.5 (a, i) or Huh-106 (e) cells producing HDV RNAs
were inoculated with high (black bars) vs. low (hatched bars) MOIs of live HCV (MOI= 0.01 and 0.1 FFU/cell; a), HBV (MOI= 20 and 200 GE/cell; e) or
DENV (MOI= 0.01 and 0.1 FFU/cell; i) particles. Supernatants and lysates from these cells were harvested at day 5 (HCV, DENV) and day 7 (HBV) post
infection. HDV-expressing cells without subsequent infection (referred to as “HDV”) as well as naive cells only infected with HCV, HBV, or DENV, as
indicated in legends below each graph, were used as controls. Supernatants from HCV/HDV (b), HBV/HDV (f), or DENV/HDV (j) co-infected cells or
corresponding control cells were used to infect Huh-7.5 (c, k) or Huh-106 (g) cells. Infection levels were assessed at day 7 post infection. Nucleic acids
present in ﬁltered cell supernatants (b, f, and j) and lysates of producer (a, d, and g) or target cells (a, f, and i) were extracted and puriﬁed for quantiﬁcation
of HDV (a–c, e–g, and i–k) and HCV RNA (a–c), HBV DNA (e–g), or DENV (i–k) RNA by qPCR. The results expressed in GE (genome equivalent) are
displayed as means (n= 2 (a–c, e–g) or n= 3 (i–k) independent experiments) per mL of cell supernatants for extracellular nucleic acids or, for intracellular
nucleic acids, per mL of cell lysates containing 106 cells. Extracted RNAs were reverse-transcribed and were PCR-ampliﬁed with HDV-speciﬁc primers to
reveal the size of transcribed HDV genomes (HDV RNA unit length), as shown below the graphs. Huh-7.5 (d, l) or Huh-106 (h) cells co-infected with HDV
and HCV (d), HBV (h), or DENV (l) were ﬁxed 7 days after infection, stained for HDAg and HCV-NS5A, HDAg and HBcAg, and HDAg and DENV-E,
respectively, and counterstained with Hoechst to visualize the nuclei. HDAg (green channel), HCV-NS5A, HBcAg, DENV-E (red channels), and nuclei (blue
channel) were then visualized by immunoﬂuorescence. Scale bars represent 20 µm. Source data are provided as a Source Data ﬁle. Error bars correspond
to standard deviation. Statistical analyses (Student’s t-test): p < 0.05 (*); p < 0.01 (**)
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Fig. 7 HCV propagates HDV particles in vivo. Four- to eight-week-old NOD-FRG mice were engrafted with primary human hepatocytes (PHH). After ca.
2–3 months, the animals displaying HSA levels >15mg/mL were split into 10 different groups (n= 4 to n= 8 independent animals) that were infected with
HDV (107 GE/mouse) and/or HCV (1.5 × 105 FFU/mouse) or HBV (108 GE/mouse), as shown in the schedule (a). At different time points post infection,
blood samples (50 µl) were collected and the viremia in sera was monitored by qPCR on the genomes of the indicated viruses (GE/mL of serum) (b). The
graphs show the mean results of viremia of HDV (red lines), HBV (blue lines), and HCV (black lines). See results of individual mice as well as of control
groups, inoculated with HDV only (Group#9: HDV) or with PBS (Group#10: Mocks) in Supplementary Fig. 7. Source data are provided as a Source Data
ﬁle. Error bars correspond to standard deviation
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signals modulating direct as well as indirect interactions of the GP
cytoplasmic tails with nucleocapsid components have been
described54,55. Thus, different scenarios could explain how HDV
RNPs may incorporate non-HBV glycoproteins. Besides factors
allowing colocalization and/or interactions between GP and
nucleocapsids, the budding and subsequent envelopment of viral
particles requires the curvature and scission of the host mem-
brane concomitant with the inclusion of nucleocapsid compo-
nents. The driving force for budding can be provided by the
nucleocapsid itself, via speciﬁc inner structural proteins (e.g., Gag
precursor of HIV) that “pushes” a virion membranous bud
through the cytoplasmic side of a membrane. Alternatively,
budding can be driven by an envelope GP that, by forming a
symmetric lattice (e.g., prME GP of ﬂaviviruses) or alternatively, a
cellular vesiculation (e.g., G protein of VSV), “pulls” the mem-
brane, creates a bud in which the nucleocapsid can be incorpo-
rated. Although there are many subtle variations and/or
combinations between these two main models56, it is intriguing
that the enveloped viruses that induce an efﬁcient release of HDV
particles (this report) are known to form subviral particles, i.e.,
nucleocapsid-free vesicles coated with envelope GPs, which
typically pertain to the “pull” model of virion assembly/budding.
Indeed, in addition to their own infectious particles, HBV46,
VSV57, HCV58,59, DENV60, and WNV61 can release their GPs in
sediment, vesicular forms, which, at least for HBV, HCV and
ﬂaviviruses are assembled and released in the ER lumen or ER-
derived compartment. Conversely, the GPs from retroviruses
such as RD114, MLV or HIV, and inﬂuenza virus are released
from the plasma membrane and/or late endosomes upon incor-
poration at the surface of infectious virions54 but they have not
been described to form SVPs, a characteristic compatible with
their inability to assemble HDV particles (Fig. 5). It is puzzling
that VSV-G, which induces the formation of infectious virions
from the plasma membrane62, allows efﬁcient HDV particles
release. Yet, we cannot exclude that formation of VSV-G subviral
particles may also occur in the lumen of the ER or, alternatively,
that HDV RNP could be targeted beneath the plasma membrane,
in addition to that of the ER.
Importantly, we show that the formation of infectious HDV
particles with unconventional GPs could also occur via coinfec-
tion with live viruses different from HBV, as shown by their
release from HCV/HDV or DENV/HDV co-infected cells. We
presume that this occurs through the same mechanisms of HDV
RNP assembly and envelopment in SVPs formed by either virus
type, as proposed above. Noteworthy, our results reveal that HDV
particles can be propagated by HCV in experimentally co-infected
mice, indicating that, in this in vivo setting at least, HDV can be a
satellite of a virus genus totally unrelated to HBV. This raises the
possibility that in nature, HDV could be associated with different
virus types, including human viral pathogens, which could pos-
sibly favor previously unappreciated HDV transmission scenarios
and modulate their pathogenicity. Indeed, hepatitis D is a most
aggressive form of hepatitis that affects ca. 15–20 million persons
worldwide, with high disparities around the world43. While the
clinical course of acute HDV infection is hardly distinguishable
from acute hepatitis B63, chronic HDV infection worsens liver
diseases caused by HBV, even though HBV replication is often
suppressed64–66. Longitudinal cohort studies have shown that
chronic hepatitis D induces a threefold higher risk of progression
to cirrhosis as compared with patients infected by HBV only67.
HDV replicates in hepatocytes and the pathologic changes it
induces are limited to the liver, which are characterized by
hepatocyte necrosis and inﬂammatory inﬁltrates that may cor-
relate with intrahepatic replication levels68. Thus, since HDV
RNA can persist in the liver in the absence of HBV for at least
6 weeks69, its propagation could be triggered upon superinfection
by other hepatitis viruses such as HCV as well as other viral
infections. Why HDV infection in patients has not been reported
in association with HCV infection is uncertain and raises inter-
esting scenarios. It is possible that direct or indirect (e.g.,
immune-mediated) interference mechanisms may impede in the
long-term HDV/HCV co-infections in vivo, though this may
occur in different contexts. For example, HDV-induced activation
of the innate immune response, which is known to have little/no
effect on HDV itself70,71, may impact several markers of coin-
fection, such as for HCV that is interferon-sensitive in contrast to
HBV72,73. Thus, what might determine eventual successful vs.
sporadic transmission and propagation of HDV with non-HBV
helper viruses would reside in the balance between biochemical
and virological compatibility of HDV RNP with the GPs of these
helper viruses vs. potential immunological mechanisms of inter-
ference, though the immune status of individuals, such as
immune suppression, may also favor transmission of such HDV
co-infections. Overall, our demonstration that unconventional
cell transmission of HDV is experimentally possible in vivo
warrants that studies be conducted in infected individuals.
Methods
Cells. Huh-749 hepatocarcinoma and Huh-10633 (a subclone of NTCP-expressing
Huh-7 cells) cells were grown in William’s E medium (Invitrogen, France) sup-
plemented with nonessential amino acids, 2 mM L-glutamine, 10 mM HEPES
buffer, 100 U/mL of penicillin, 100 µg/mL of streptomycin, and 10% fetal bovine
serum (FBS). Huh-7.5 cells (kind gift of C Rice) and 293T kidney (ATCC CRL-
1573) cells were grown in Dulbecco’s modiﬁed minimal essential medium (DMEM,
Invitrogen) supplemented with 100 U/mL of penicillin, 100 µg/mL of streptomycin,
and 10% FBS. The C6/36 Aedes albopictus cells (ATCC CRL-1660) were grown in
DMEM medium supplemented with 100 U/mL of penicillin, 100 µg/mL of strep-
tomycin, L-glutamine, and 10% FBS at 28 oC.
Plasmids. pSVLD3 plasmid encodes HDV RNP27,29. Plasmids pT7HB2.7 for
HBV29, phCMV-VSV-G for vesicular stomatitis virus (VSV), phCMV-JFH1-E1E2
for hepatitis C virus (HCV), phCMV-RD114 and phCMV-RD114TR for cat
endogenous virus, phCMV-MLV-A for amphotropic murine leukemia virus
(MLV), phCMV-HIV for human immunodeﬁciency virus (HIV), phCMV-NA and
phCMV-HA for avian inﬂuenza virus (AIV), phCMV-LCMV for lymphocytic
choriomeningitis virus (LCMV), phCMV-FgsHMPV for human metapneumovirus
(HMPV), phCMV-PrME for dengue virus (DENV), and West Nile virus (WNV)
encode the envelope surface glycoproteins of the indicated viruses36,74,75.
Antibodies. The HDAg antigen was detected with the SE1679 rabbit polyclonal
antibody for western-blot and immunoﬂuorescence experiments. The human anti-
E2 AR3A39 (kind gift from M Law), mouse anti-VSV-G 41A158, and mouse anti-
HBsAg Hs33 (Cat # GTX41723, GeneTex) monoclonal antibodies (mAb) were
used in neutralization and immunoprecipitation assays. The mouse anti-CD81 JS-
81 (Cat # 555675 BD Pharmingen) and anti-LDLr C7 (Cat # sc-18823, Santa Cruz
Biotechnology) mAbs were used for receptor-blocking experiments. The mouse
anti-DENV-E 3H5 mAb (kind gift from P Desprès), the mouse anti-NS5A 9E10
mAb (kind gift of C Rice), and the human anti-HBcAg (from an anti-HBcAg-
positive and anti-HBsAg-negative patient) serum were used for
immunoﬂuorescence.
HDV particle production and infection. Huh-7 cells were seeded in 10-cm plates
at a density of 106 cells per plate and were transfected with a mixture of 2.5 µg of
pSVLD3 plasmid and 10 µg of plasmid, allowing the expression of surface envelope
glycoproteins of the above-mentioned viruses29 using FuGENE 6 transfection
reagent (Promega). Transfected cells were grown for up to 9 days in primary
hepatocyte maintenance medium containing 2% FBS and 2% DMSO to slow cell
growth76. Supernatants of virus-expressing cells were separated from the producer
cells, ﬁltered through 0.45-µm-pore ﬁlters, and were analyzed by RT-qPCR for
detection of HDV RNA28, using the methodologies and primers described below.
These supernatants were also used for infection experiments in Huh-106 and other
target cells, which were seeded in 48-well plates at a density of 1.5 × 104 cells
per well.
Transfected or infected cells were cultured in primary hepatocyte maintenance
medium containing 2% FBS and 2% DMSO following infection to slow cell growth.
Infectivity of viral particles was assessed 7 days post infection by RT-qPCR of HDV
RNA isolated from cell lysates or by determining focus-forming units in ethanol-
ﬁxed plates using HDAg antibodies. For neutralization and receptor-blocking
experiments, 100 ng/mL of antibodies were incubated with virus particles for 1 h at
37 oC before addition to the cells.
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For puriﬁcation of viral particles, 10 mL of producer cell supernatants were
harvested, ﬁltered through a 0.45-μm ﬁlter, and centrifuged at 32,000 rpm for 4 h at
4 °C on a 30% sucrose cushion with a SW41 rotor and Optima L-90 centrifuge
(Beckman). Pellets were resuspended in 100 µL of TNE (50 mM Tris-HCl, pH 7.4,
100 mM NaCl, and 0.1 mM EDTA) prior to use for immunoprecipitation and
western blot of HDAg or for northern blot of RNAs.
For inhibition of farnesyltransferase in producer cells, we used Lonafarnib
(Sigma-Aldrich), an inhibitor of prenylation that prevents HDV assembly37,38.
Following transfection with pSVLD3 plasmid and GP expression plasmid, as
described above, Huh-7 cells were maintained in a daily-changed medium
supplemented with 0.2% DMSO and 400 mM DTT alone or in the presence of
1 mM Lonafarnib. The cell supernatants were used for infection experiments in
Huh-106 as described above.
RT-qPCR detection of HDV RNAs. Total RNA from serum, ﬁltrated cell super-
natant, or from virus producer or infected cells washed with phosphate-buffer
saline (PBS) was extracted with TRI Reagent according to the manufacturer’s
instructions (Molecular Research Center) and treated with RNAse-free DNase (Life
Technologies). RNAs were reverse-transcribed using random oligonucleotide pri-
mers with iScript cDNA synthesis kit (Bio-Rad) before quantiﬁcation by qPCR, as
described below.
For strand-speciﬁc HDV RNA RT-qPCR30,31, extracted RNAs were reverse-
transcribed with High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems) to amplify either genomic or antigenomic cDNAs by using primers
DSg: 5′-CCGGCTACTCTTCTTTCCCTTCTCTCGTC for genomic-sense cDNA
synthesis and DSag: 5′-CACCGAAGAAGGAAGGCCCTGGAGAACAA for
antigenomic-sense cDNA synthesis. The qPCR assay was then performed, as
described below.
The genomic and antigenomic HDV RNAs used as standards for this strand-
speciﬁc RT-qPCR assay were obtained by in vitro transcription of HDV DNA
amplicons ﬂanked by T7 promoters. The full-length HDV amplicons were
ampliﬁed by PCR from pSVLD3 plasmid with primers T7HD 687–706: 5′-
CAATTCTAATACGACTCACTATAGGGAGAA GGCCGGCATGGTCCCAGCC
TC (with T7 promoter sequences) and HDVgR: 5′-ATCAGGTAAGAAAGGA
TGGAACGCGGACCC for the amplicon allowing synthesis of the genomic HDV
RNA standards and, for the amplicon allowing synthesis of the antigenomic HDV
RNA standards, with primers HDVgF: 5′-GGCCGGCATGGTCCCAGCCTC and
AgT7HD 685–656: 5′-CAATTCTAATACGACTCACTATAGGGAGAAA TCAGGT
AAGAAAGGATGGAACGCGGACCC (with T7 promoter sequence). Either
amplicon was transcribed from T7 promoters using a commercially available kit
according to the manufacturer’s instructions (RiboMAXTM Express T7, Promega).
The full-length linear RNAs were treated with RNase-free DNase, followed by RNA
puriﬁcation (GeneJET RNA puriﬁcation kit, Thermo Fisher Scientiﬁc) and
quantiﬁed using a Nanodrop device (Thermo Fisher Scientiﬁc). These artiﬁcial
genomic or antigenomic HDV RNAs were diluted in RNase-free water and stored
at −80 °C in single-use aliquots and were used as calibration standards for strand-
speciﬁc HDV RNA RT-qPCR31,32,77. The copy numbers in genomic or
antigenomic HDV RNAs extracted from cells or supernatants were quantiﬁed
using 10-fold dilution series of either genomic or antigenomic HDV RNA
standards processed in parallel. We deduced that 106 HDV RNA molecules
(genomic or antigenomic) are equal to 1 pg of the corresponding HDV RNA
standard. The speciﬁcity of the strand-speciﬁc RT-qPCR assay was investigated by
the quantiﬁcation of genomic and antigenomic RNA standards (artiﬁcial RNA)
with the correct primer and the respective opposite primer (genomic primer on
antigenomic HDV RNA standard and vice versa) (Supplementary Fig. 1f).
Unspeciﬁc reverse transcription with the opposite primer occurred, though in a
very limited extent (<0.000001%).
The following speciﬁc oligonucleotides were then used for HDV cDNA
quantiﬁcation:31,32 forward (Kuo F: 5′-GGACCCCTTCAGCGAACA) and reverse
(Kuo R: 5′-CCTAGCATCTCCTCCTATCGCTAT) primers. The qPCR was
performed using FastStart Universal SYBR Green Master (Roche Applied Science)
on a StepOne Real-Time PCR System (Applied Biosystems).
As an internal control of extraction, in vitro-transcribed exogenous RNAs from
the linearized Triplescript plasmid pTRI-Xef (Invitrogen) were added into the
samples prior to RNA extraction and quantiﬁed with speciﬁc primers (Xef-1a
970L20: 5′-CGACGTTGTCACCGGGCACG and Xef-1a 864U24: 5′-
ACCAGGCATGGTGGTTACCTTTGC). All values of intracellular HDV RNAs
were normalized to GAPDH gene transcription. For GAPDH mRNA
quantiﬁcation, we used as forward primer, hGAPDH 83U: 5′-AGGTGAA
GGTCGGAGTCAACG and as a reverse primer, hGAPDH 287 L: 5′-TGGAAG
ATGGTGATGGGATTTC.
RT-PCR assays. Total RNA from cells or supernatants was extracted with TRI
Reagent according to the manufacturer’s instructions (Molecular Research Center).
RNAs were reverse-transcribed with SuperScript III reverse transcriptase kit (Invi-
trogen) using a strand-speciﬁc primer HDV gRNA: 5′-ATCAGGTAAGAAAGGA
TGGAACGCGGACCC that detects the genomic HDV RNA and allows ampliﬁca-
tion of antigenomic-sense cDNA. The reverse-transcribed cDNA products were used
to perform a PCR using the following speciﬁc oligonucleotides to amplify the unit-
length HDV genome: forward (HDVgF: 5′-GGCCGGCATGGTCCCAGCCTC) and
reverse (HDVgR: 5′-ATCAGGTAAGAAAGGATGGAACGCGGACCC) primers.
The PCR bands were visualized on propidium iodide-stained agarose gels.
Northern blots. The puriﬁed RNA was subjected to electrophoresis through a 2.2
M formaldehyde, 1.2% agarose gel, and transferred to a nylon membrane. The
membrane-bound RNA was hybridized to a 32P-labeled RNA probe speciﬁc for
genomic HDV RNA49. Quantiﬁcation of radioactive signals was achieved using a
phosphorimager (BAS-1800 II; Fuji). Uncropped and unprocessed scans of all blots
are provided in the Source Data ﬁle.
Western blots. The proteins from pelleted cell supernatants or extracted from
total cell lysates were denatured in Laemmli buffer at 95 oC for 5 min and were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then
transferred to nitrocellulose membranes (GE Healthcare). Membranes were
blocked with 5% nonfat dried milk in PBS and incubated at 4 °C with the SE1679
rabbit anti-HDAg serum at a 1/500 dilution in PBS–0.01% milk, followed by
incubation with a IRdye secondary antibody (Li-Cor Biosciences). Membrane
visualization was performed using an Odyssey infrared imaging system CLx (LI-
COR Biosciences). Uncropped and unprocessed scans of all blots are provided in
the Source Data ﬁle.
Immunoprecipitation of HDV particles. For immunoprecipitation, 50 µL of
Dynabeads Protein G (Thermo Scientiﬁc) bound with 10 µg of anti-HBsAg Hs33,
anti-E2 AR3A, or anti-VSV-G 41A1 mAbs were incubated for 1 h at room tem-
perature with puriﬁed virus particles. The beads were then washed three times with
1 mL of PBS with 0.02% Tween-20. The RNA was extracted from the complex with
Tri Reagent and detected by RT-qPCR.
Equilibrium-density gradients. One milliliter of cell supernatant containing virus
particles harvested at 9 days post transfection was loaded on top of a 3–40%
continuous iodixanol gradient58 (Optiprep, Axis Shield). Gradients were cen-
trifuged for 16 h at 4 °C in Optima L-90 centrifuge (Beckman). Thirteen fractions
of 900 µl were collected from the top and used for refractive index measurement
and RNA quantiﬁcation, as described above.
Electron microscopy. One milliliter of cell supernatant containing virus particles
harvested at 9 days post transfection was mixed with 100 µL of heparin–agarose
beads (Sigma) preequilibrated with 10 mM Tris-HCL and 100 mM NaCl buffer
(pH 8). Unbound particles were washed off ﬁve times with 10 mM Tris-HCL, 200
mM NaCl buffer (pH 8), and the particles were eluted from the heparin–agarose
beads with 10 mM Tris-HCL, 800 mM NaCl buffer (pH 8). For negative staining in
electron microscopy, 5 µL of sample solution was applied onto a glow-discharged
EM grid coated with amorphous carbon. After 1 min of sample adsorption, the
excess solution was blotted away using a piece of ﬁlter paper and the grid was put
onto a drop of 1% (w/v) sodium silicotungstate staining solution. After 30 s, excess
stain solution was blotted away as before and the grid was dried in air. The samples
were examined using a transmission electron microscope Philips CM120 operating
at 120 kV.
Coinfection assays. Huh-7.5 cells seeded in six-well plates at a density of 8 × 104
cells per well producing HDV RNAs were superinfected 3 days later cells with Jc1
HCVcc, HBV, or DENV live, helper virus particles78,79. Lysates and supernatants
of infected cells were harvested at 5 days post infection from the producer cells and
were analyzed by qPCR for detection of HDV28, HCV58, HBV78, and DENV
nucleic acids. The supernatants containing HDV and either helper virus particles
were used for infection experiments in relevant target cells. Infectivity was assessed
at 7 days later by qPCR of HDV (see above) and of helper virus RNAs or DNAs
isolated from cell lysates, using the following speciﬁc oligonucleotides: for HCV,
forward HCV U147: 5′-TCTGCGGAACCGGTGAGTA and reverse HCV L277: 3′-
TCAGGCAGTACCACAAGGC primers; for HBV, forward HBV-SUF: 5′-
TCCCAGAGTGAGAGGCCTGTA and reverse HBV-SUR: 5′-ATCCTCGAGAA
GATTGACGATAAGG primers; and for DENV, forward DENV NSF: 5′-ACCT
GGGAAGAGTGATGGTTATGG and reverse DENV NSR: 5′-ATGGTCTCTGG
TATGGTGCTCTGG primers.
Immunoﬂuorescence. Producer or infected cells were ﬁxed with 4% paraf-
ormaldehyde (Sigma-Aldrich, France) for 15 min and permeabilized with 0.1%
Triton X-100 (Sigma-Aldrich) for 7 min. Fixed cells were then saturated with 3%
bovine serum albumin (BSA)/PBS for 20 min and incubated for 1 h with primary
antibodies diluted in 1% BSA/PBS at the following dilutions:80 anti-HDAg SE1679
rabbit polyclonal serum, 1/500; anti-DENV-E 3H5 mAb, 1/800; anti-NS5A 9E10
mAb, 1/1,000; and anti-HBcAg serum, 1/500. After three washes with 1% BSA/
PBS, cells were incubated for 1 h with the corresponding secondary antibodies
(Molecular Probes, The Netherlands) at a 1/1000 dilution: donkey anti-rabbit Alexa
Fluor 488 (Cat # A-21206); donkey anti-mouse Alexa Fluor 555 (Cat # A-31570);
and goat anti-human Alexa Fluor 555 (Cat # A-21433) sera. Cells were washed
three times with PBS and then stained for nuclei with Hoechst 33342 (Molecular
Probes) for 5 min. After two washes in PBS, cells were imaged with an Axiovert
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135M microscope (Zeiss, Germany) equipped with a DC350FX camera (Leica,
Germany), and images were analyzed with the ImageJ software (imagej.nih.gov).
In vivo experiments. All experiments were performed in accordance with the
European Union guidelines for approval of the protocols by the local ethics
committee (Authorization Agreement C2EA-15, “Comité Rhône-Alpes d’Ethique
pour l’Expérimentation Animale”, Lyon, France—
APAFIS#1570–2015073112163780). Primary human hepatocytes (PHH, Corning,
BD Gentest) were intrasplenically injected into FRG mice40, a triple-mutant mouse
knocked out for fumarylacetoacetate hydrolase (fah–/–), recombinase-activating
gene 2 (rag2–/–), and interleukin 2 receptor gamma chain (IL2rg–/–), 48 h after
adeno-uPA conditioning41,42. Mice were subjected to NTBC cycling during the
liver repopulation process41. Mice with human serum albumin (HSA) levels >
15 mg/mL, as determined using a Cobas C501 analyzer (Roche Applied Science),
were inoculated with virus preparations by intraperitoneal injection. Sera were
collected at different time points before and after infection. Mice were killed
10–14 weeks post infection.
Statistical analysis. Data are shown as means ± standard deviations. Statistical
analyses were performed using two-sample Student’s t tests assuming unequal
variance. The p-values are represented according to the following convention: p >
0.05 (nonsigniﬁcant, ns); p < 0.05 (*); p < 0.01 (**).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during this study are available from the corresponding author
upon reasonable request. The source data underlying ﬁgures and Supplementary Figures
are provided as a Source Data ﬁle.
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Supplementary Figure 1. Quantification of genomic and antigenomic HDV RNAs in lysates and supernatants of cells producing HDV, VSV-
∆p, and HCV-∆p particles. (a, b) Huh-7 cells were co-transfected with pSVLD3 plasmid coding for HDV RNPs and plasmids coding for either HBV, 
VSV or HCV surface glycoproteins (GP), resulting in “HDV”, “VSV-∆p”, and “HCV-∆p” samples, respectively. As control, pSVLD3 was co-transfected 
with an empty plasmid (“No GP” samples). At day 3, 6 or 9, extracellular HDV RNAs were quantified from cell supernatants by using a strand-specific 
RTqPCR assay for genomic (gRNA) (a) and anti-genomic (agRNA) (b) HDV RNAs. Intracellular HDV gRNA and agRNA RNAs were quantified from 
cell lysates at day 9. HDV RNAs in GE (genome equivalent) are expressed as means (N=4 independent experiments) per mL of cell supernatants for 
extracellular RNAs or, for intracellular RNAs, per ml of cell lysates containing 106 cells. No significant increase of HDV agRNAs over time post-
transfection could be detected in the supernatants (b), in sharp contrast to the extracellular HDV gRNAs that increased by up to 1,000-fold (a). (c) 
The enrichment of HDV gRNAs in secreted particles is reflected by calculating the gRNA/agRNA ratios in HDV, VSV-∆p or HCV-∆p particles from the 
supernatants and in cell lysates. Particularly, at day 9 post-transfection, the gRNA/agRNA ratios in particles are up to 800-fold higher than the 
gRNA/agRNA ratios in the cell lysates. (d, e) “Secretion Indexes” (SI) were calculated for HDV gRNAs (SIgRNA) (d) and for HDV agRNAs (SIagRNA) (e) 
by normalizing extracellular RNAs detected in cell supernatants for HDV, VSV-∆p or HCV-∆p to the “No GP” condition. (f) The strand-specific 
RTqPCR assay allowing quantification of gRNAs or agRNAs was calibrated and validated using either 1011 genomic (G) or antigenomic (AG) HDV 
RNA standards that had been transcribed in vitro as templates to detect unspecific quantification. The results indicate specific detection of either 
template and very low detection of opposite templates. Error bars correspond to standard deviation. Statistical analyses (Student’s t-test): p <0.05 (*).
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Supplementary Figure 2. DMSO supplementation in producer cell culture media does not affect production of HDV particles. Huh-7 cells 
were co-transfected with pSVLD3 plasmid coding for HDV RNPs and plasmids coding for either HBV “HDV”, VSV “VSV-∆p” or HCV “HCV-∆p” 
envelope glycoproteins (GP). As control, Huh-7 cells were transfected with pSVLD3 plasmid without envelope proteins (No GP) or were not 
transfected (NT).(a-c) The cells were cultured for 6 days in primary hepatocyte maintenance medium (see Methods section) containing (+DMSO), or 
not (-DMSO), 2%DMSO to slow cell growth, as indicated. Cell toxicity assessment was performed with the LDH (Pierce Cytotoxicity Assay Kit) using 
the indicated positive and negative controls of the kit (a). The cell supernatants were then filtered and the extracellular RNA was extracted and 
purified before quantifying HDV gRNAs by strand-specific RTqPCR (b). Huh-106 cells were inoculated with the above supernatants. Infected cells 
were grown for 7 days before total intracellular RNA was purified (c). The quantification of intracellular viral nucleic acids in lysates of infected cells 
were normalized with GAPDH RNAs. The results of HDV gRNAs quantification by strand-specific RTqPCR assays are expressed in GE (genome 
equivalent) and are displayed as means per mL of cell supernatants for extracellular nucleic acids or, for intracellular nucleic acids, per mL of cell 
lysates containing 106 cells. Source data are provided as a Source Data file. Error bars correspond to standard deviation.
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Supplementary Figure 3. Electron microscopy analysis of 
HDV particles produced with VSV and HCV glycoproteins. 
Huh-7 cells were co-transfected with pSVLD3 plasmid coding for 
HDV RNPs and plasmids coding for either HBV “HDV”, VSV 
“VSV-∆p” or HCV “HCV-∆p” envelope glycoproteins (GP) (a) or 
were only transfected with plasmids encoding the above GPs, as 
indicated (c). As controls, an empty plasmid was co-transfected 
with pSVLD3 (a) or transfected alone (c) (referred to as “No GP”). 
At day 6 post-transfection, the cell supernatants were harvested, 
filtered and purified on heparin beads. Particles were eluted and 
observed by electron microscopy after negative staining. The 
scale bars represent 100 nm. The panels in (a) show examples 
of particles produced by co-transfection of pSVLD3 plasmid and 
plasmids encoding HBsAg (HDV), VSV-G (VSV-∆p), or HCV-
E1E2 (HCV-∆p) while the panels in (c) show examples of 
particles produced by transfection of plasmids encoding either 
GP alone. Note that large, i.e., with diameters of 35-40 (white 
arrows) and small, i.e., with diameters of 25-30 nm (black arrows) 
particles can be detected in (a) whereas only small particles can 
be detected in (c). See quantification of either particle type (b, d). 
nd, not detectable. Source data are provided as a Source Data 
file. Error bars correspond to standard deviation.
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Supplementary Figure 4. Secretion and infectivity of HDV particles enveloped with different GP from 293T cells. (a) Cell culture media from 
293T cells were harvested at day 6 or 9, as indicated, upon co-transfection of pSVLD3 plasmid coding for HDV RNPs and plasmids coding for HBV 
(HDV), VSV (VSV-∆p), HCV (HCV-∆p), DENV (DENV-∆p), WNV (WNV-∆p) or HMPV (HMPV-∆p) envelope glycoproteins. As control, pSVLD3 was 
transfected without envelope proteins (No GP). The cell supernatants were filtered and the extracellular RNA was extracted and purified before 
quantifying HDV RNAs by RTqPCR. The quantification of intracellular HDV RNAs in cells producing the HDV particles at day 9 post-transfection and 
normalized with GAPDH RNAs are also shown. HDV RNAs in GE (genome equivalent)/mL are expressed as means (N=5 independent experiments) 
per ml of cell lysates containing 106 cells. (b) The infectivity of virus particles present in the cell supernatants that were harvested at day 6 or 9 post-
transfection was determined in Huh-106 (NTCP-expressing Huh-7 cells) cells. Infected cells were grown for 7 days before total intracellular RNA was 
purified. The results of HDV RNAs quantification by RTqPCR are expressed as means after normalization with GAPDH RNAs. The dotted lines 
represent the experimental thresholds, as defined with the “No GP” controls. Source data are provided as a Source Data file. Error bars correspond to 
standard deviation. Statistical analyses (Student’s t-test): p <0.05 (*); p <0.01 (**).
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Supplementary Figure 5. Immunofluorescence of HDV RNA-expressing cells superinfected with HBV, HCV and DENV. (a) mock-infected 
cells (Mock) or cells expressing HDV RNAs that were inoculated with live HCV (HDV/HCV), HBV (HDV/HBV) or DENV (HDV/DENV) viruses were 
fixed, stained for HDAg and HCV-NS5A, HDAg and HBcAg and HDAg and DENV-E, as indicated, counterstained with Hoechst to visualize the 
nuclei. HDAg (green channel), HCV-NS5A, HBcAg, DENV-E (red channels) and nuclei (blue channel), and were then visualized by 
immunofluorescence. Scale bars represent 20 µm. (b) Controls of immunofluorescence staining. Mock-infected cells (top row), HDV-expressing 
cells (middle row) and HCV-, HBV- or DENV-infected cells (bottom row) were stained for HDAg (green), nuclei (blue) and HCV-NS5A (red, left 
column), HBcAg (red, middle column) or DENV-E (red, right column), and visualized by immunofluorescence. Scale bars represent 20 µm.
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Supplementary Figure 6. HDV/DENV productively infect and propagate in C6/36 mosquito cells. Huh-7.5 (a) or C6/36 (D) cells were 
inoculated with low (black bars) vs. high (hatched bars) inputs of HDV/DENV (MOI=0.01 and 0.1 FFU/cell for HDV and DENV, respectively) particles, 
that were purified from HDV/DENV co-infected cells (see Figure 6). Supernatants and lysates from these cells were harvested at day 5 post-
infection. The supernatants from HDV/DENV co-infected Huh-7.5 (b) or C6/36 (e) cells were used, respectively, to re-infect naïve Huh-7.5 (C) cells or 
both Huh-7.5 (f) and Huh-106 (g) cells. Infection levels were assessed at day 7 post-infection. The nucleic acids present in filtered cell supernatants 
(b, e) as well as in lysates of producer cells (a, d) and target cells (c, f, g) were extracted and purified for quantification of HDV and DENV RNA 
by RTqPCR. The quantification of intracellular RNAs in cell lysates were normalized with GAPDH RNAs. The results expressed in GE 
(genome equivalent) are displayed as means per mL of cell supernatants for RNAs or, for intracellular RNAs, per mL of cell lysates containing 
106 cells. Source data are provided as a Source Data file. Error bars correspond to standard deviation.
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Supplementary Figure 7. HCV propagates HDV particles in vivo. NOD-FRG mice, engrafted with primary human hepatocytes (PHH) for two 
months and displaying HSA levels >15 mg/mL, which corresponded to 40-70% human hepatocytes as assessed by FAH staining (data not shown), 
were split in different groups that were infected with HDV (107 GE/mouse), HBV (108 GE/mouse) and/or HCV (1.5x105 FFU/mouse), as shown in 
the schedule of Figure 7a. (a) At different time points post-infection, blood samples (50 µl) were collected and the viremia in sera was 
monitored by qPCR on genomes of the indicated viruses (GE/mL of serum). The graphs show the results of viremia of HDV (red lines), HBV 
(blue lines) and HCV (black lines) in individual mice from all groups as well as from control groups, inoculated with PBS (Mocks; Group#10) or 
with HDV only (HDV; Group#9). Note the results from two identified mice of Group#8 as displayed in the small (mouse #902) and large 
(mouse #978) dotted lines that show correlation between HCV and HDV viremia. (b) Reverse-transcribed RNAs from sera from co-infected animals 
were PCR-amplified with HDV-specific primers to reveal the size of transcribed and secreted HDV genomes (HDV RNA unit-length). The results from 
two mice per group are shown here.
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Supplementary Figure 8. 2nd study of HDV propagation in vivo by HCV. 4-8 weeks old NOD-FRG mice were engrafted with primary 
human hepatocytes (PHH). After ca. 2-3 months, the animals displaying HSA levels >15 mg/mL were split in 4 groups (N=4 to N=8 independent 
animals, see Table) that were infected with HDV (107 GE/mouse) and/or HCV (1.5x105 FFU/mouse), as shown in the schedule (a). At different 
time points post-infection, blood samples (50 µl) were collected and the viremia in sera was monitored by qPCR on the genomes of the indicated 
viruses (GE/mL of serum) (b). The graphs show the mean results of viremia of HDV (red lines) and HCV (black lines). Source data are provided as 
a Source Data file. Error bars correspond to standard deviation.
Reviewers' Comments:  
 
Reviewer #1:  
Remarks to the Author:  
NCOMMS-18-21856  
 
Hepatitis delta virus (HDV) has long been known to co-infect people in a manner dependent on the 
hepatitis B virus and, indeed, was discovered based on its association with severe hepatitis in HBV 
patients. This dependence is due to the need for the hepadnavirus envelope to release infectious 
particles containing the HDV RNA and protein enveloped by the hepadnavirus surface antigen. Perez-
Vargas et al describe results indicating that HDV might be able to use the envelope proteins of other 
viruses to produce infectious particles. The observations involve combinations of cell culture based 
experiments in which infectious HDV was found to be released from cells co-expressing the envelope 
of other viruses besides HBV, as well as experiments using mice with “humanized” livers in which HDV 
spread occurred via HCV rather than HBV, although at much lower levels. The authors findings not 
only have the potential to dramatically expand our understanding of the egress of HDV RNA-protein 
complexes from cells but also imply that HDV might affect the pathogenesis of numerous other 
viruses, as it is known to do for Hepatitis B virus. Thus, the potential impact of this study is quite 
large. However, given this potential impact, it is imperative that several weaknesses in the cell-culture 
based experiments several be addressed to convincingly demonstrate that the authors’ conclusions are 
correct. These weaknesses (addressed specifically below), in addition to inconsistencies in some of the 
data and the use of somewhat unorthodox cell culture conditions undermine confidence in the 
robustness of the experimental results.  
 
Major points  
 
1. The conclusion that infectious HDV particles are secreted from cells expressing VSV or HCV 
glycoproteins is indeed suggested by the results in Figs. 1 and 2; however, there are concerns. The 
biggest is that the purported secreted viral particles are not characterized sufficiently and the 
characterization that is provided - immunoprecipitation – raises questions about their identity. The 
immunoprecipitation of the particles is very inefficient – less than 10%. This inefficiency is masked by 
the log representation of the graph in Fig. 1B. There is no need for a log representation in this figure; 
it should be changed. It seems possible that the observed release of what are presumed to be 
enveloped particles might be just HDV RNPs. Further analysis of the particles, in particular 
determining whether the RNA is genome, antigenome or some combination of both, would help to 
conclude one way or the other. In addition, in Fig. 1B, the authors suggest a very unusual HDAg 
composition for the HDV particles released from cells co-expressing different virus glycoproteins (even 
for regular “HDV”). Numerous studies of HDV particles obtained from cells, infected animals and 
patients consistently show similar amounts of S-HDAg and L-HDAg. The authors, from labeling of the 
immunoblot, propose that the particles consist mostly of L-HDAg, with very little S-HDAg present 
(except following immunoprecipitation with anti-VSV G antibody). There is no discussion of this highly 
unusual HDAg composition. On the other hand, without showing specific L-HDAg and S-HDAg controls 
on the immunoblot, it is possible the electrophoresis is not resolving the two species (that is, the 
labeling is incorrect) and that it is not possible to determine the relative amounts of S-HDAg and L-
HDAg from the blot shown.  
 
2. A second major concern is that the authors have not conclusively shown that the particles they 
have obtained are actually infectious. Several additional experiments are necessary to prove that the 
authors are observing actual infections rather than, for example, adherence of material to cells. A time 
course showing accumulation of HDV RNA and protein over several days following incubation would be 
more convincing than a single time point on day 7. Also more convincing would be demonstration of 
antigenomic RNA accumulation (assuming that the released RNA is genome) and an increase with time 
in the amount of L-HDAg, which only occurs during replication.  
 
3. The authors included 2% DMSO in the cell cultures used to produce HDV particles and for infection 
experiments. The stated purpose was to retard cell growth. However, this treatment is unnecessary 
(2% DMSO is not typically included in experiments used to produce HDV nor to analyze infection in 
Huh 106 cells) and its use here raises questions about the generality of the results. Perhaps 2% DMSO 
is somewhat toxic (it does retard cell growth) and leads to the release of HDV from cells stressed by 
expression of certain viral glycoproteins. At least some of the production and infection experiments 
should be repeated in the absence of DMSO.  
 
Additional points  
1. There was considerable variability between some similar experiments, or unexplained 
inconsistencies. In Fig. 3, for example, the levels of HDV RNA detected in mock infected cells varied by 
almost 10-fold between panel A and panel B. While the RNA analyses suggest that HDV obtained from 
cells expressing VSV G replicates to 10-fold higher levels than HDV with an HBV envelope (Fig 2A), the 
immunofluorescence analysis shows approximately 5 times more cells positive for HDV with the HBV 
envelope (Fig. 2C).  
2. Page 3, second paragraph, second sentence. The statement that HDV does not meet the criteria for 
the definition of a virus is overstated. HDV is a satellite virus, with HBV as the only known helper.  
3. Figure 5. The legend describes black and gray bars, there are only solid black and hashed bars.  
4. Supplemental Fig. 1; Group 9. According to the table in Fig. 6, only 4 animals were in this group, 
yet there are about 9 lines on the graph. There is no indication of what the colors represent in this 
graph nor on any of the others in this figure.  
 
 
 
Reviewer #2:  
Remarks to the Author:  
Perez-Vargas et al. report that hepatitis D virus (HDV), which was thought to be a cognate satellite 
virus of hepatitis B Virus (HBV), may be enveloped by the surface glycoproteins (GPs) from a variety 
of viruses for its assembly and the release. The authors also found that the production and infection of 
HDV is not restricted to liver cells, but is restricted by the GPs enveloping HDV and the corresponding 
receptors expressed on cells. The authors performed various cell culture and animal experiments to 
support their observations. Co-expression of HDV RNPs and individual viral GP (HBV, VSV, HCV, etc) in 
hepatoma cell lines led to release of infectious HDV particles. The infection of different GP-enveloped 
HDV could be blocked by antibodies to the corresponding viral envelop proteins. Notably, in both HBV 
or HCV infected mice HDV viremia was detected, confirming the observations in a physiologically 
relevant experimental system.  
Based on these lines of evidence, the authors propose that HDV may have an origin independent of 
HBV, and could potentially be propagated by viruses other than HBV. The authors observation is 
surprising, given the scarcity of literature hinting HDV infection in the absence of an HBV infection. 
The authors have carved a unique angle to investigate the HDV propagation and provided both cell 
culture and animal evidences to support their hypothesis, which if proven true will enrich our 
understanding of HDV origin and the interplay of different viruses. However, several issues need to be 
addressed to further validate their hypothesis.  
 
Major issues:  
1. In figure 1 and figure 4, the key plasmid pSVLD3 was first developed in the Taylor lab (Kuo, et al, 
1989, J. Virol) as a trimer of HDV genome and used for HDV replication. However, as it was indicated 
later (Taylor, 2006, Curr Top Microbiol Immunol), that the unit-length genomic or antigenomic HDV 
RNA was mostly DNA-directed rather than RNA-directed, and since this does not recapitulate the 
authentic HDV replication, an improved construct was made to have slightly larger than one unit 
length to produce RNA-derived transcripts (Lazinski & Taylor, 1994, J. Virol). The data produced in 
Figure 1 and 4 may not hold if the production of HDV RNPs is formed in way that deviates from the 
authentic mechanism. Two methods could be used: 1) NTCP expressing cells/cell lines expressing 
various viral GPs is infected by recombinant HBV enveloped HDV virus to test if infectious HDV 
particles is secreted, and 2) use the improved constructs to validate the findings.  
 
2. In figure 1a, the release of virus through cell death should be ruled out.  
 
Minor issues:  
1. Figure 1b, the VSV-∆p 41A1 has a different pattern, e.g, much more s-HDAg and a 55 kDa band. A 
discussion of the difference, cause, and implication would be helpful.  
 
2. Figure 2c should include light-field or nuclei staining.  
 
3. Figure 5, it is not clear what is the HDV-RNA expressing cell, what construct is used to drive HDV-
RNA expression?  
 
4. Is there any explanation why the HDV infection is not reported to be dependent on HCV, if HCV 
propagates HDV indeed rather efficiently?  
 
5. At numerous occasions the authors refer to “data not shown”. This reviewer regards it as important 
to show all data relevant to the study in the manuscript  
 
6. Page 4: “While HDV was expressed…” rephrase as RNA is not expressed but transcribed or in this 
case replicated. Proteins are expressed.  
 
7. Page 8, line: please correct/spell out the mutant alleles in the FRG mice: fumarylacetoacetate 
hydrolase (fah-/-), recombinase activating gene 2 (rag2-/-), interleukin 2 receptor gamma chain 
(IL2RgNULL)  
 
8. Page 12: subheading, delta particle NOT particles  
 
 
 
Reviewer #3:  
Remarks to the Author:  
The origin of HDV attracts many interesting speculations. Current study proposed it coming from 
cellular circular RNAs that captured by HBV envelopes, so it is possible other viruses also enabling the 
packaging of naked HDV RNPs. They tested several viruses, such as HCV, dengue, HIV, et al, and 
showed HCV, denge and WNV, among others, coudl package the HDV RNPs into their envelope 
proteins and pass the HDV into next round of infections in cell cultures or in human hepatocyte 
chimera mice.  
 
Though the results appeared to be interesting, their validation of pseudo-typed HDV and its infections 
is incomplete and many basic HDV RNA and proteins analysis are missing.  
 
The comments are for authors' reference.  
1. The claimed of packaging of HDV RNP by HBV Surface proteins, or by VSV or HCV GPs are 
interesting by in vitro co-transfection. This finding is supported by their immune-precipitation of these 
pseudo-typed HDVs, using anti-HBs or anti-VSV or anti-HCV GP. However, the validation of these 
packaged HDV falls far behind. To confirm the packaged HDV RNP, the authors only showed an 
ambiguous detection of so-called HDV large HDAg, but not HDV RNA. It is essentially to include a HDV 
virus packaged by HBV surface protein as a positive control. Such virion has to contain the HDV small 
delta antigen, and genomic HDV RNA, other than the so-called large HDAg. A Northern blot to confirm 
an intact, full-sized HDV RNA is required. The RT-PCR quantitation cannot distinguish the viral 
genemic vs. antigenomic HDV RNAs, either about the size. (In fact, the large HDAg detected in 
western blot appeared to be suspicious. Other HDAg-specific antibody is required, as it is difficult to 
understand why no small HDAg is co-packaged).  
2. The packaging of HDV RNP by HBsAg required specific isoprenylation of large HDAg. Do the rescue 
of HDV RNPs require the same modification or not ? This can be easily studied by using isoprenylation 
inhibitor currently available.  
3. The authors tried to band the VSV or HCV GP-packaged HDV virions by CsCL gradient analysis. 
They succeeded in identifying the putative pseudo-typed HDV in unique density fractions. Again, their 
only data based upon RT-PCR assay for HDV RNA. Northern and western blots to show HDV genomic 
RNA and both large and small delta antigens are essential. Finally, as the HDV virions are so 
abundant, it is necessary to do a simple EM study for these fractions to visualize the size, distribution 
of these pseudo-type HDV particles.  
4. In their co-infection experiments, though HCV or other viruses appeared able to rescue the 
intracellular HDV RNPs and resulted in efficient next round infections, the data are not comprehensive. 
The authors relied only HDV RNA quantification by RT-PCR, however, they failed to provide either 
northern blot or western blot to show the simultaneous presence of HDV RNA or delta antigens. These 
are easily to show, as the HDV RNA titiers are so high by their data. Besides, it is important to 
document the co-presence of HDAg and HCV antigen or dengue virus antigen in the same human 
hepatocytes from the chimera mice. Without these collaborating data, the HDV RNA RT-PCR seems 
shaky. It should be pointed that currently there is no approved HDV RNA assays, and many in-house 
assays suffer from varying or inconsistent performance.  
 
5. Finally, the HCV or dengue virus infections in humanized chimera mice took a lot of effort and 
showed intriguing results. Other than insufficient virological data as mentioned in point 3, the authors 
may need to study the natural HCV/HDV coinfection in human intravenous drug abusers who 
frequently co-infected by HBV/HDV/HCV. Do these patients carry HDV RNA within HCV envelope ?  
Dr. François-Loïc Cosset   
Scientific and Executive Director 
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December 2nd, 2018 
 
 
 
Dear Reviewers 
 
 
Please find enclosed our revised manuscript entitled “Enveloped viruses distinct from HBV induce 
dissemination of hepatitis D virus in vivo” by Jimena Perez-Vargas, Fouzia Amirache, Bertrand Boson, 
Chloé Mialon, Camille Sureau, Floriane Fusil, and myself, which we would like to publish in Nature 
Communications as a Research Article. 
 
We greatly appreciated the Editor and Reviewers’ helpful and constructive comments, which we have 
all taken into account to improve our manuscript by performing additional experiments. Overall, we 
believe that we have succeeded to provide a more detailed description of these novel HDV particles 
and to clarify most issues raised by all Reviewers in this revised version of our manuscript.  
We have revised the manuscript accordingly (see manuscript copy with changes underlined) and we 
provide a point-by-point response to these comments below (in blue). 
 
The additional results, as per Reviewers’ requests, are:  
- Northern blot analysis of HDV particles produced with unconventional GPs (Figure 1C) and of 
cells infected with these particles (Figure 3D). 
- Determination by strand-specific RT-PCR of HDV RNA unit size in HDV particles produced with 
unconventional GPs (Figure 1B, Figure 1H), with live viruses (Figure 6), and in sera of co-
infected animals (Supplemental Figure 7). 
- Western blot analysis of HDV particles produced with HBV, VSV and HCV glycoproteins (Figure 
1D) and of cells infected with these particles (Figure 3E). 
- Electron microscopy analysis of HDV particles produced with HBV, VSV and HCV glycoproteins 
(Figure 1F and Supplemental Figure 3). 
- Quantitative analysis of HDV intracellular and extracellular RNAs by strand-specific RTqPCR 
assays that detect genomic and antigenomic RNAs (Figure 3 and Supplemental Figure 1). 
- Use of Lonafarnib in production (and subsequent infection) experiments (Figure 3A, B). 
- Time-course analysis of genomic vs. antigenomic HDV RNAs and of L-HDAg and S-HDAg 
forms in infected cells (Figure 3C, D). 
- Assessment of co-infection of cells by HDV and live helper viruses (HBV, HCV and DENV) by 
immuno-fluorescence assays (Figure 5D and Supplemental Figure 5). 
- Demonstration that HDV particles can be formed with non-HBV glycoproteins both via 
transfection of pSVLD3 plasmid and via infection with “helper-free” HDV particles in GP-
expressing cells (Supplemental Figure 6). 
 
The other important changes in our revised manuscript are: 
- Statistical analysis of the data. 
- Assessment of production of HDV particles by HDV/DENV-co-infected mosquito cells 
(Supplemental Figure 6). 
- Demonstration that identical production of HDV particles can be achieved from cells cultured in 
media containing, or not, 2% DMSO (Supplemental Figure 2). 
- Results of co-infection by HDV and HCV in a second cohort of human liver mice (N=24; 
Supplemental Figure 8). 
- Reorganization of the manuscript text, figures and supplementary figures to address, on the 
whole, all comments of the Reviewers. 
 
We thank you very much for your interest and time in considering our revised manuscript for publication 
in Nature Communications. 
  
Sincerely yours, 
            
Dr. FL Cosset   
Point-by-point Reply (see literature cited at the end of this document) 
 
Reviewer #1 (Remarks to the Author): 
 
Hepatitis delta virus (HDV) has long been known to co-infect people in a manner dependent on the 
hepatitis B virus and, indeed, was discovered based on its association with severe hepatitis in HBV 
patients. This dependence is due to the need for the hepadnavirus envelope to release infectious 
particles containing the HDV RNA and protein enveloped by the hepadnavirus surface antigen. Perez-
Vargas et al describe results indicating that HDV might be able to use the envelope proteins of other 
viruses to produce infectious particles. The observations involve combinations of cell culture based 
experiments in which infectious HDV was found to be released from cells co-expressing the envelope 
of other viruses besides HBV, as well as experiments using mice with “humanized” livers in which HDV 
spread occurred via HCV rather than HBV, although at much lower levels. The authors findings not only 
have the potential to dramatically expand our understanding of the egress of HDV RNA-protein 
complexes from cells but also imply that HDV might affect the pathogenesis of numerous other viruses, 
as it is known to do for Hepatitis B virus. Thus, the potential impact of this study is quite large. However, 
given this potential impact, it is imperative that several weaknesses in the cell-culture based experiments 
several be addressed to convincingly demonstrate that the authors’ conclusions are correct. These 
weaknesses (addressed specifically below), in addition to inconsistencies in some of the data and the 
use of somewhat unorthodox cell culture conditions undermine confidence in the robustness of the 
experimental results. 
 
Major points 
1. The conclusion that infectious HDV particles are secreted from cells expressing VSV or HCV 
glycoproteins is indeed suggested by the results in Figs. 1 and 2; however, there are concerns. The 
biggest is that the purported secreted viral particles are not characterized sufficiently and the 
characterization that is provided - immunoprecipitation – raises questions about their identity. The 
immunoprecipitation of the particles is very inefficient – less than 10%. This inefficiency is masked by 
the log representation of the graph in Fig. 1B. There is no need for a log representation in this figure; it 
should be changed. It seems possible that the observed release of what are presumed to be enveloped 
particles might be just HDV RNPs. Further analysis of the particles, in particular determining whether 
the RNA is genome, antigenome or some combination of both, would help to conclude one way or the 
other. In addition, in Fig. 1B, the authors suggest a very unusual HDAg composition for the HDV particles 
released from cells co-expressing different virus glycoproteins (even for regular “HDV”). Numerous 
studies of HDV particles obtained from cells, infected animals and patients consistently show similar 
amounts of S-HDAg and L-HDAg. The authors, from labeling of the immunoblot, propose that the 
particles consist mostly of L-HDAg, with very little S-HDAg present (except following 
immunoprecipitation with anti-VSV G antibody). There is no discussion of this highly unusual HDAg 
composition. On the other hand, without showing specific L-HDAg and S-HDAg controls on the 
immunoblot, it is possible the electrophoresis is not resolving the two species (that is, the labeling is 
incorrect) and that it is not possible to determine the relative amounts of S-HDAg and L-HDAg from the 
blot shown. 
Reply: We have addressed these points and we are happy to provide a more detailed characterization 
of VSV-∆p and HCV-∆p particles, as described below : 
1 - Demonstration that HDV RNAs in particles are genomes rather than antigenomes. We used a 
strand-specific RTqPCR assay (Li et al., 2006) to quantify HDV genomic RNA (gRNA) and antigenomic 
RNA (agRNA) in lysates and supernatants of transfected and/or infected cells (see new Supplemental 
Figure 1A). The enrichment of HDV gRNAs (panel A) in secreted particles is reflected by the 
gRNA/agRNA ratios (panel C), which were up to 800-fold higher in HDV, VSV-∆p or HCV-∆p particles 
than in the lysates of their corresponding producer cells. As shown in panels B and E, we noted no 
significant increase over time post-transfection of the low amounts of HDV agRNAs detected in the 
supernatants, in sharp contrast to the extracellular HDV gRNAs that increased by up to 1,000-fold 
(panels A and D). Owing to the high sensitivity of the RTqPCR assay, these low levels HDV agRNAs 
could be due to some background of cell death induced by the combination of GP transfection and 
extended culture conditions of these cells (up to 9 days). Note that identical extracellular HDV agRNAs 
levels were detected for VSV-∆p and HCV-∆p particles as compared to “normal” HDV particles (i.e., with 
HBV GPs). We believe that these new results show that HDV particles generated with unconventional 
GP incorporate full-length genomic RNA. 
2 - Improvement regarding the detection of HDAg species present in viral particles. We replaced 
the HDAg co-IP analysis, which was not possible to improve at this stage, by a Western blot analysis of 
the different types of HDV particles that were purified by ultracentrifugation on a sucrose cushion. The 
results clearly show that both L-HDAg and S-HDAg are incorporated at similar levels and ratios in the 
purified viral particles generated with HCV and VSV GPs as compared to “normal” HDV particles 
produced with HBV GPs.  
3 – Concerning the RNA coIP that precipitated 5 to 11% of HDV RNAs, we do not expect that the 
efficiency could be higher because of the competition exerted by the SVPs for either type of particles 
that outnumber the infectious particles. We respectfully request to keep the log representation of the 
graph in Figure 1E, in order to better show the results of the Flow through RTqPCR values. 
 
2. A second major concern is that the authors have not conclusively shown that the particles they have 
obtained are actually infectious. Several additional experiments are necessary to prove that the authors 
are observing actual infections rather than, for example, adherence of material to cells. A time course 
showing accumulation of HDV RNA and protein over several days following incubation would be more 
convincing than a single time point on day 7. Also more convincing would be demonstration of 
antigenomic RNA accumulation (assuming that the released RNA is genome) and an increase with time 
in the amount of L-HDAg, which only occurs during replication. 
Reply: We have performed all these experiments. The panels C-E of the new Figure 3 provides a time 
course analysis in infected cells over several days following inoculation. Using a strand-specific 
RTqPCR assay for HDV RNA, we show that not only genomic HDV RNAs but also antigenomic RNAs 
are amplified from day 3 to day 9 post-infection and accumulate in infected cells (panel C). Likewise, we 
confirm by Northern blot analysis of these infected cells that HDV RNAs accumulate in these cells (Panel 
D). Finally, we show that HDAg protein levels also increase with a progressive appearance of L-HDAg, 
which marks productive infection (panel E).  
In addition to the other pieces of evidence such as i) inoculation of cell expressing vs. not expressing 
the receptors (now Figure 4A), ii) co-infection and transmission assays with live helper viruses (now 
Figure 6 and Supplemental Figure 6) and iii) propagation in experimentally infected animals (now Figure 
7 and Supplemental Figures 7 & 8), we believe that altogether, these results convincingly show that the 
particles are infectious. 
 
3. The authors included 2% DMSO in the cell cultures used to produce HDV particles and for infection 
experiments. The stated purpose was to retard cell growth. However, this treatment is unnecessary (2% 
DMSO is not typically included in experiments used to produce HDV nor to analyze infection in Huh 106 
cells) and its use here raises questions about the generality of the results. Perhaps 2% DMSO is 
somewhat toxic (it does retard cell growth) and leads to the release of HDV from cells stressed by 
expression of certain viral glycoproteins. At least some of the production and infection experiments 
should be repeated in the absence of DMSO. 
Reply: We used Williams E-based medium for production or infection with HDV particles in Huh-7-
derived cells (including Huh-106 and Huh-7.5 cells). While this Reviewer is correct to say that DMSO-
containing medium is not typically included in such experiments, we supplemented our medium with 2% 
DMSO in this study since, when we started the project, the current procedures to grow hepatocyte-
derived cell lines for several days recommended such media both to maintain cell differentiation 
(Bauhofer et al., 2012, Sainz & Chisari, 2006) and to induce or maintain NTCP expression (Watashi et 
al., 2014, Yan et al., 2012). For example, it was shown that DMSO-containing media strongly increase 
HDV and HBV infection efficacy in HepG2NTCP and Huh-7NTCP cells, as compared to DMSO-free media 
(Iwamoto et al., 2014, Ni et al., 2014).  
Importantly, as requested by this Reviewer, we now show in the new Supplemental Figure 2, first, that 
2% DMSO does not induce more cell toxicity as compared to cell cultures grown in DMSO-free medium 
(panel A) and, second, that omitting DMSO does not change the production levels and infectivity of 
HDV, VSV-∆p and HCV-∆p particles (panels B and C).  
 
Additional points 
1. There was considerable variability between some similar experiments, or unexplained 
inconsistencies. In Fig. 3, for example, the levels of HDV RNA detected in mock infected cells varied by 
almost 10-fold between panel A and panel B. While the RNA analyses suggest that HDV obtained from 
cells expressing VSV G replicates to 10-fold higher levels than HDV with an HBV envelope (Fig 2A), the 
immunofluorescence analysis shows approximately 5 times more cells positive for HDV with the HBV 
envelope (Fig. 2C). 
Reply: The previous immunofluorescence analysis of Figure 2C was displayed to provide a qualitative 
assessment of HDAg nuclear localization upon infection. As requested by this Reviewer, we have 
repeated the experiment and we provide in the revised Figure 2B images that are more consistent with 
the quantification of infectivity (now shown in Figure 2C) and that include nuclei staining with Hoechst.  
As for the variability between panel A and panel B of previous Figure 3 (now Figure 4), i.e., there is 3- 
to 5-fold differences in the HDV RNA RTqPCR results obtained for the mock-treated supernatants for 
panel A vs. panel B. This is explained by the fact that either experiment type (i.e., neutralization in panel 
A and receptor blocking in panel B) was performed at different sessions of the study, which induces 
experimental variations. Yet, we had made sure that the sizes of the HDV, VSV-∆p and HCV-∆p particles 
inputs in either panel A or panel B were identical in order to provide accurate comparisons between 
conditions in each panel.  
 
2. Page 3, second paragraph, second sentence. The statement that HDV does not meet the criteria for 
the definition of a virus is overstated. HDV is a satellite virus, with HBV as the only known helper. 
Reply: We have removed this sentence as requested.  
 
3. Figure 5. The legend describes black and gray bars, there are only solid black and hashed bars. 
Reply: We have corrected the legend in this Figure (now revised Figure 6).  
 
4. Supplemental Fig. 1; Group 9. According to the table in Fig. 6, only 4 animals were in this group, yet 
there are about 9 lines on the graph. There is no indication of what the colors represent in this graph 
nor on any of the others in this figure. 
Reply: We thank this Reviewer for pointing this. Like for the “Mocks” group (Group #10), but also in 
other groups (not shown, for sake of clarity), we tested the samples for all three viruses (HBV, HCV and 
HDV) in Group #9, whose mice were infected with HDV only, and this is now indicated in the revised 
legend with the indicated color codes (blue: HBV; black: HCV; red: HDV). Note that one animal died 
after week 8 (P4), which explains that there are 9 lines after P4 (12 lines until P4) in this graph. 
 
 
Reviewer #2 (Remarks to the Author): 
 
Perez-Vargas et al. report that hepatitis D virus (HDV), which was thought to be a cognate satellite virus 
of hepatitis B Virus (HBV), may be enveloped by the surface glycoproteins (GPs) from a variety of 
viruses for its assembly and the release. The authors also found that the production and infection of 
HDV is not restricted to liver cells, but is restricted by the GPs enveloping HDV and the corresponding 
receptors expressed on cells. The authors performed various cell culture and animal experiments to 
support their observations. Co-expression of HDV RNPs and individual viral GP (HBV, VSV, HCV, etc) 
in hepatoma cell lines led to release of infectious HDV particles. The infection of different GP-enveloped 
HDV could be blocked by antibodies to the corresponding viral envelop proteins. Notably, in both HBV 
or HCV infected mice HDV viremia was detected, confirming the observations in a physiologically 
relevant experimental system. 
Based on these lines of evidence, the authors propose that HDV may have an origin independent of 
HBV, and could potentially be propagated by viruses other than HBV. The authors observation is 
surprising, given the scarcity of literature hinting HDV infection in the absence of an HBV infection. The 
authors have carved a unique angle to investigate the HDV propagation and provided both cell culture 
and animal evidences to support their hypothesis, which if proven true will enrich our understanding of 
HDV origin and the interplay of different viruses. However, several issues need to be addressed to 
further validate their hypothesis. 
 
Major issues: 
1. In figure 1 and figure 4, the key plasmid pSVLD3 was first developed in the Taylor lab (Kuo, et al, 
1989, J. Virol) as a trimer of HDV genome and used for HDV replication. However, as it was indicated 
later (Taylor, 2006, Curr Top Microbiol Immunol), that the unit-length genomic or antigenomic HDV RNA 
was mostly DNA-directed rather than RNA-directed, and since this does not recapitulate the authentic 
HDV replication, an improved construct was made to have slightly larger than one unit length to produce 
RNA-derived transcripts (Lazinski & Taylor, 1994, J. Virol). The data produced in Figure 1 and 4 may 
not hold if the production of HDV RNPs is formed in way that deviates from the authentic mechanism. 
Two methods could be used: 1) NTCP expressing cells/cell lines expressing various viral GPs is infected 
by recombinant HBV enveloped HDV virus to test if infectious HDV particles is secreted, and 2) use the 
improved constructs to validate the findings. 
Reply: We thank this Reviewer for pointing out the original reference to this key construct, which is duly 
cited now (Kuo et al., 1989). Regarding his/her specific point, we had used in Figure 6 a variation of the 
method #1 he/she suggested. Accordingly, following infection of naïve cells with VSV-∆p particles (i.e., 
“helper-free” VSV-G enveloped HDV particles), the cells were superinfected with live HCV, HBV or 
DENV viruses. The results show that we could rescue infectious HDV particles, indicating that both 
pSVLD3 transfection and “helper-free” HDV infection (such as VSV-∆p) processes leads to expression 
of HDV RNA that can be transmitted as infectious particles. Note that a similar conclusion can be 
deduced from the mouse infection data since these animals were inoculated with “helper-free” HBsAg-
enveloped HDV virus before, after or concomitantly with live HCV or HBV (Figure 7).  
Finally, we show in the new Supplemental Figure 6 the results of transmission experiments using both 
Huh-7.5 human hepatoma and C6/36 mosquito cells that were infected with supernatants from 
HDV/DENV co-infected cells. We found that these secondary HDV/DENV-infected Huh-7.5 and C6/36 
cells could replicate, assemble and transmit infectious HDV particles to tertiary cells.  
In our opinion, these results also demonstrate that HDV RNA can be transmitted via processes that 
involve authentic HDV replication.  
 
2. In figure 1a, the release of virus through cell death should be ruled out. 
Reply: We now provide indirect evidence to address this point, which is very difficult to formally rule out 
since most of the GPs studied here can intrinsically cause cell death (albeit through different pathways). 
We evaluated the cytotoxicity in transfected cells at different time points of collection of HDV, VSV-∆p, 
and HCV-∆p particles as well as in No GP (i.e., pSVLD3-transfected cells) and non-transfected control 
cells. Using the Pierce Cytotoxicity Assay Kit, we obtained similar levels of LDH release for both VSV-
∆p or HCV-∆p particles and “normal” HDV particles but also for the No GP control and the non-
transfected condition as shown at day 6 post-transfection in the new Supplemental Figure 2. Thus, we 
conclude that while the combination of long-term culture and transfection procedure is somehow harmful 
to cells, the release of particles may not occur through cell death first, since otherwise, the No GP control 
(transfected with pSVLD3 only) would induce secretion of HDV RNAs from these cells, and second, 
since one may conclude that “classical” HDV particles would also be released through cell death.  
Note that slightly increased cytotoxicity levels were obtained when producing VSV-∆p particles; this was 
expected owing to the previously known fusogenic activity of VSV-G (see e.g., (Arai et al., 1998) for 
VSV-G-pseudotyped lentiviral vectors), which, ultimately, does not preclude production of such vectors. 
 
Minor issues: 
1. Figure 1b, the VSV-∆p 41A1 has a different pattern, e.g, much more s-HDAg and a 55 kDa band. A 
discussion of the difference, cause, and implication would be helpful. 
Reply: We agree with this issue of this Reviewer, which was also pointed out by the two other 
Reviewers. Accordingly, we have replaced this HDAg co-IP analysis, which was difficult to improve, by 
a Western blot analysis of the different types of HDV particles that were purified by ultracentrifugation 
on a sucrose cushion. The results unambiguously show that both L-HDAg and S-HDAg are incorporated 
at similar levels and ratios in the purified viral particles generated with HCV and VSV GPs as compared 
to “normal” HDV particles produced with HBV GPs.  
 
2. Figure 2c should include light-field or nuclei staining. 
Reply: As requested by this Reviewer, we have repeated the experiment and we provide in the revised 
Figure 2B images that show nuclei staining (Hoechst) in inoculated cells.  
 
3. Figure 5, it is not clear what is the HDV-RNA expressing cell, what construct is used to drive HDV-
RNA expression? 
Reply: We infected these cells with VSV-G-coated HDV particles (VSV-∆p). Cells were then super-
infected with the indicated live viruses (see our reply to Major issue #1 of this Reviewer).  
 
4. Is there any explanation why the HDV infection is not reported to be dependent on HCV, if HCV 
propagates HDV indeed rather efficiently?  
Reply: We are deeply interested by finding an explanation to this question, which is also raised by 
Reviewer #3. Indeed, one of our future plans is to attempt detection of HCV-dependent HDV propagation 
in selected patient cohorts, which is difficult clinically and logistically. As for tentative explanation, it is 
possible that direct or indirect (e.g., immune-mediated) interference mechanisms may impede in the 
long term HDV/HCV co-infections in vivo, though they may occur in different contexts. For example, 
HDV-induced activation of the innate immune response, which is known to have little/no effect on HDV 
itself (Alfaiate et al., 2016, Zhang et al., 2018), may impact several markers of co-infection, such as for 
HCV that is interferon-sensitive in contrast to HBV (Lutgehetmann et al., 2011, Mutz et al., 2018). 
Thus, overall, we propose that what might determine eventual successful vs. sporadic transmission and 
propagation of HDV with non-HBV helper viruses would reside in the balance between 
biochemical/virological HDV RNP compatibility with the GP of these helper viruses vs. potential 
(immunological) mechanisms of interference, though the immune status of individuals, such as immune-
suppression, may favor transmission of such HDV co-infections. 
This putative explanation is included in the revised Discussion. 
 
5. At numerous occasions the authors refer to “data not shown”. This reviewer regards it as important 
to show all data relevant to the study in the manuscript 
Reply: We have complied with the request of this Reviewer and we now display these data not shown 
in Figure 3 (kinetics of HDV replication in infected cells), in Figure 5 (results of infectivity for all HDV/GP 
combinations), in Supplemental Figure 5 (assessment of co-infection by IF), in Supplemental Figure 6 
(infection of mosquito cells), and in Supplemental Figure 8 (results of infection from a second cohort of 
HuHep mice). The only results that are not shown are the FAH staining of humanized livers, as they 
have been published previously by us (Calattini et al., 2015) and others (Bissig et al., 2010). 
 
6. Page 4: “While HDV was expressed…” rephrase as RNA is not expressed but transcribed or in this 
case replicated. Proteins are expressed.  
Reply: We have changed this sentence to “While HDV RNA accumulated…” 
 
7. Page 8, line: please correct/spell out the mutant alleles in the FRG mice: fumarylacetoacetate 
hydrolase (fah-/-), recombinase activating gene 2 (rag2-/-), interleukin 2 receptor gamma chain 
(IL2RgNULL) 
Reply: We have also modified this sentence accordingly (revised Material and Methods). 
 
8. Page 12: subheading, delta particle NOT particles 
Reply: We have introduced the requested change in this subheading. 
 
 
Reviewer #3 (Remarks to the Author): 
 
The origin of HDV attracts many interesting speculations. Current study proposed it coming from cellular 
circular RNAs that captured by HBV envelopes, so it is possible other viruses also enabling the 
packaging of naked HDV RNPs. They tested several viruses, such as HCV, dengue, HIV, et al, and 
showed HCV, denge and WNV, among others, coudl package the HDV RNPs into their envelope 
proteins and pass the HDV into next round of infections in cell cultures or in human hepatocyte chimera 
mice. 
Though the results appeared to be interesting, their validation of pseudo-typed HDV and its infections 
is incomplete and many basic HDV RNA and proteins analysis are missing. 
 
The comments are for authors' reference. 
 
1. The claimed of packaging of HDV RNP by HBV Surface proteins, or by VSV or HCV GPs are 
interesting by in vitro co-transfection. This finding is supported by their immune-precipitation of these 
pseudo-typed HDVs, using anti-HBs or anti-VSV or anti-HCV GP. However, the validation of these 
packaged HDV falls far behind. To confirm the packaged HDV RNP, the authors only showed an 
ambiguous detection of so-called HDV large HDAg, but not HDV RNA. It is essentially to include a HDV 
virus packaged by HBV surface protein as a positive control. Such virion has to contain the HDV small 
delta antigen, and genomic HDV RNA, other than the so-called large HDAg. A Northern blot to confirm 
an intact, full-sized HDV RNA is required. The RT-PCR quantitation cannot distinguish the viral genemic 
vs. antigenomic HDV RNAs, either about the size. (In fact, the large HDAg detected in western blot 
appeared to be suspicious. Other HDAg-specific antibody is required, as it is difficult to understand why 
no small HDAg is co-packaged). 
Reply: We have performed these experiments and we provide in this revised manuscript a more detailed 
characterization of VSV-∆p and HCV-∆p particles : 
1 – Incorporation of genomic HDV RNA in viral particles.  
First, we provide in revised Figure 1C a result of Northern blot that confirm the presence of an intact, 
full-sized HDV RNA is pellets of particles purified by ultracentrifugation on a 30% sucrose cushion.  
Second, we used a strand-specific RTqPCR assay (see revised Material and Methods) to quantify HDV 
genomic RNA (gRNA) and antigenomic RNA (agRNA) in lysates and supernatants of transfected and/or 
infected cells (see new Supplemental Figure 1A). The enrichment of HDV gRNAs (panel A) in secreted 
particles is reflected by the gRNA/agRNA ratios (panel C), which were up to 800-fold higher in HDV, 
VSV-∆p or HCV-∆p particles than in the lysates of their corresponding producer cells.  
Third, we designed a RT-PCR strand-specific “banding” assays with primers that allow amplification of 
the HDV genomic RNA. We found that HDV particles contains HDV RNA at the expected size of 1.7 kb, 
whether they were produced by transfection with pSVLD3 and GP-expression plasmids (Figure 1B, 1H) 
or by co-infection with live HCV, HBV or DENV in vitro (Figure 6) and in experimentally-infected animals 
(Supplemental Figure 7). 
Fourth, showing that VSV-∆p and HCV-∆p form particles, we performed Electron Microscopy analysis 
of particles (Figure 1C and Supplemental Figure 3), which were obtained from cell supernatants purified 
with heparin beads, as discussed below in Point #3. 
2 - Detection of HDAg species present in viral particles. We replaced the HDAg co-IP analysis, 
which was not possible to improve, by a Western blot analysis of the different types of HDV particles 
that were pelleted by ultracentrifugation on a sucrose cushion. The results (Figure 1D) clearly show that 
both L-HDAg and S-HDAg are incorporated at similar levels and ratios in the purified viral particles 
generated with HCV and VSV GPs as compared to “normal” HDV particles produced with HBV GPs. 
 
2. The packaging of HDV RNP by HBsAg required specific isoprenylation of large HDAg. Do the rescue 
of HDV RNPs require the same modification or not ? This can be easily studied by using isoprenylation 
inhibitor currently available. 
Reply: We have performed the requested experiment and we show, in Figure 3A & B, that Lonafarnib, 
an isoprenylation inhibitor that prevents HDV assembly and secretion (Bordier et al., 2003), could readily 
inhibit production and hence, transmission and replication of HDV RNA from HDV, VSV-∆p and HCV-
∆p particles, suggesting a shared pathway of the early assembly process leading to production of all 
HDV particle types. 
 
3. The authors tried to band the VSV or HCV GP-packaged HDV virions by CsCL gradient analysis. 
They succeeded in identifying the putative pseudo-typed HDV in unique density fractions. Again, their 
only data based upon RT-PCR assay for HDV	 RNA. Northern and western blots to show HDV genomic 
RNA and both large and small delta antigens are essential. Finally, as the HDV virions are so abundant, 
it is necessary to do a simple EM study for these fractions to visualize the size, distribution of these 
pseudo-type HDV particles. 
Reply: We performed the requested experiment but failed to detect HDV RNA by Northern blot in that 
specific case, owing to their insufficient concentrations in fractions from density gradients. Indeed, the 
HDV RNA copy number required to perform Northern blots (>107 copies/lane – i.e., 20µl loaded – are 
needed) allowed detection of full-sized HDV RNA in the 100-fold pelleted viral particles shown in Figure 
1C but not in the fractions from iodixanol density gradients, owing to dilution of the sample in the 
gradient. Note that the aim of this latter experiment was to performed density gradient analysis from 
unprocessed, crude supernatants (in order to maintain native state of the sample) and that these 
supernatants contain ca. 4x107 copies /mL for HCV-∆p particles (thus, the most HDV RNA-enriched 
fraction contain less than 2x105 copies/20µl, which is below the threshold level). As for detection of L-
HDAg and S-HDAg, while we concentrated the fractions with methanol/acetone, the signals were not of 
sufficient quality for being displayed in Figure 1 owing to BSA levels that interfered with migration in 
SDS-Page.   
To overcome these technical issues and address the request of this Reviewer regarding the packaging 
of full-sized HDV RNA, we used the above-mentioned RT-PCR banding assays and we show that the 
RTqPCR-positive fractions contain HDV RNA at the expected genomic size of 1.7 kb (Figure 1G). 
As for EM studies, we provide in Figure 1F and Supplemental Figure 3 images of particles which were 
obtained from cell supernatants purified with heparin beads. We observed two types of spheres with 
diameters of 35-40 and 25-30 nm (Gudima et al., 2007). The small spheres likely corresponded to sub-
viral particles since they were also detected when VSV-G and HCV-E1E2 were expressed alone, similar 
to HBV GPs (Supplemental Figure 3C & D) whereas the large spheres, that were only detected when 
HDV RNA were co-expressed with either GP (Supplemental Figure 3A & B), could correspond to VSV-
∆p and HCV-∆p particles. While the concentration of these particles appeared insufficient to allow simple 
EM studies from the fractions of density-gradients, we believe that this consolidate the characterization 
of these novel HDV particles. 
 
4. In their co-infection experiments, though HCV or other viruses appeared able to rescue the 
intracellular HDV RNPs and resulted in efficient next round infections, the data are not comprehensive. 
The authors relied only HDV RNA quantification by RT-PCR, however, they failed to provide either 
northern blot or western blot to show the simultaneous presence of HDV RNA or delta antigens. These 
are easily to show, as the HDV RNA titers are so high by their data. Besides, it is important to document 
the co-presence of HDAg and HCV antigen or dengue virus antigen in the same human hepatocytes 
from the chimera mice. Without these collaborating data, the HDV RNA RT-PCR seems shaky. It should 
be pointed that currently there is no approved HDV RNA assays, and many in-house assays suffer from 
varying or inconsistent performance. 
Reply: We show in the revised set of figures a more detailed characterization of these co-infection 
experiments. 
First, regarding the presence of full-sized HDV RNA, using the above-mentioned RT-PCR banding 
assays, we show that cells co-infected with HDV and HCV or HBV or DENV express and secrete RNAs 
at the expected genomic size of 1.7 kb, which matches the detection of these RNAs by RTqPCR. 
Second, we performed an immunofluorescence (IF) analysis of these co-infected cells to document the 
co-presence of HDAg with HCV, HBV or DENV antigens in the same human hepatocytes. As shown in 
the revised Figure 6 and new Supplemental Figure 5, in addition to cells that were mono-infected by 
either virus type, we could readily detect cells co-expressing the antigens of either virus combinations 
(HDAg with HBV core, HDAg with HCV NS5A or HDAg with DENV E), which indicates that cells were 
co-infected by HDV and HCV, HBV or DENV. 
Third, regarding the chimera mice, we performed an IF analysis of liver sections from the co-infected 
animals. While we could readily detect mono- and co-infected hepatocytes in HBV/HDV co-infected 
mice, as shown previously by others (Lutgehetmann et al., 2012), the IF analysis of HDV/HCV infected 
animals was more difficult (see Figure below) and displayed rare co-infected cells with dull HDAg 
immunofluorescence, which may be explained at this stage by the following reasons. First, as the levels 
of HCV RNAs in this human liver mouse model are typically ca. 10-30 fold less elevated than for HBV, 
the propagation of HDV is less favorable with HCV helper virus than with HBV and results in a smaller 
proportion of infected hepatocytes. Second, at the time these animals were sacrificed (i.e., at week 14 
post-infection (Figure 7A)), the levels of HDV RNAs had decreased by over two-logs as compared to 
previous time-points (see e.g., week 8 for Group#8 in Figure 7), which made the analysis difficult to do. 
Third, we think that HDV and HCV interfere with each other, perhaps in a stronger manner that the 
previously known HDV/HBV interference (Alfaiate et al., 2016, Lutgehetmann et al., 2012), and this will 
be the subject of a further study of our team. Indeed, it is possible that direct or indirect (e.g., immune-
mediated) interference mechanisms may impede in the long term HDV/HCV co-infections in vivo, though 
they may occur in different contexts. For example, HDV-induced activation of the innate immune 
response, which is known to have little/no effect on HDV itself (Alfaiate et al., 2016, Zhang et al., 2018), 
may impact several markers of co-infection, such as HCV that is interferon-sensitive in contrast to HBV 
(Lutgehetmann et al., 2011, Mutz et al., 2018). Thus, if this is acceptable, we respectfully request to 
this Reviewer that we do not display the IF results from the infected mice as they warrant further 
studies beyond the scope of this first study. We also believe that the results IF analyses of co-infection 
in vitro requested by this Reviewer are meaningful to establish the co-presence of HDV and live helper 
viruses. 
Finally, using the above-mentioned PCR banding assays, we show that sera from mice co-infected with 
HDV and HCV or HBV contain RNAs at the expected genomic size of 1.7 kb, in agreement with the 
presence these RNAs by RTqPCR, which supports our conclusion that the unconventional HDV 
particles can be secreted and propagated in vivo.  
 
5. Finally, the HCV or dengue virus infections in humanized chimera mice took a lot of effort and showed 
intriguing results. Other than insufficient virological data as mentioned in point 3, the authors may need 
to study the natural HCV/HDV coinfection in human intravenous drug abusers who frequently co-
infected by HBV/HDV/HCV. Do these patients carry HDV RNA within HCV envelope ? 
Reply: This is clearly a highly important and interesting question that we wish to pursue in the follow up 
work of this pioneer study. Indeed, how to best address this and reach statistical significance, given that 
natural HCV/HDV coinfections in human must be very rare in our opinion, is the subject of on-going 
discussions with clinicians who may collaborate with us on this issue. Yet, identifying and forming the 
different patient cohorts (e.g., from human intravenous drug abusers, as proposed by this Reviewer) or 
just accessing to collections of samples will require time, not only because we do not yet know exactly 
which are the best types of individuals to screen but also because getting the necessary ethical permits 
(and funding) is a difficult enterprise, particularly when it deals with countries where HDV is currently 
prevalent, like Mongolia and South America in the Amazonian basin. Finally, while Western countries, 
particularly Italia, have been severely hit by HDV infection in the 80’s, recovering the collections of 
specimens from infected patients and their complete clinical description is difficult and will also take 
several months.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Immunohistochemistry of livers from HDV/HCV co-infected HuHep mice. 4-8 weeks old NOD-FRG 
mice were engrafted with primary human hepatocytes (PHH). After ca. 2-3 months, the animals displaying HSA 
levels >15 mg/mL were split in different groups that were infected with HDV alone (107 GE/mouse) (top panels), 
with HDV and HBV (108 GE/mouse) (lower left panel), or with HDV and HCV (1.5x105 FFU/mouse) (lower right 
panel). Tissue samples of animals sacrificed at week 14 post-infection (see Figure 7A) were fixed in 10% buffered 
formalin and embedded in paraffin. 4 µm-thick tissue sections of formalin-fixed, paraffin-embedded tissue were 
prepared according to conventional procedures.  
For immunofluorescence, sections were incubated with a rabbit anti-HDAg antibody, then the OmniMap Detection 
Kit was used with a FITC kit (lefts panels) or with a rhodamine kit (right panels). After stripping of the first antibody, 
sections were incubated with a human anti-HBcAg with an OmniMap Detection Kit and rhodamine kit (lower right 
panel) or with a mouse anti-NS5A 9E10 with an OmniMap Detection Kit and a rhodamine kit (lower left panel). 
Dapi were used for counterstaining. The slides were scanned with a panoramic scan II (3D histech, Hungary). Scale 
bars represent 20 µm. 
Note that livers of animals infected with HDV alone did not display HDAg-positive cells, owing to the late time point 
at sacrifice and probable extinction of HDV RNA replication in the absence of helper virus. In contrast, cells mono-
infected by HDV (green arrows in left panel and red arrows in right panel), by HBV (red arrows in lower left 
panel) or HCV (green arrows in lower right panel), or co-infected could be detected (yellow arrows in lower 
panels). Note that the number of HDV/HCV co-infected cells is significantly lower than for HDV/HBV co-infection, 
in line with the lower viremia of the former (see Figure 7B and Supplemental Figures 7 & 8), and that HDV/HCV 
HDAg immunofluorescence is less bright than for the latter, which denotes negative interference between the two 
viruses. 
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Reviewers' Comments:  
 
Reviewer #1:  
Remarks to the Author:  
This is a frustrating process. The authors are proposing potentially very interesting and important 
results. Their overall proposal may well fit very nicely with recent observations that viruses closely 
related to HDV exist in other species in the absence of any hepadnavirus (Wille, 2018; Hetzel, 2018 - 
the authors would do well to incorporate this information in their discussion). However, and 
unfortunately, the manuscript still has problems.  
 
1. Fig. 1D – the image appears to have been manipulated. The right hand side of the HDV, VSV-∆p 
and HCV-∆p lanes has been cropped in the same manner. Furthermore, on close inspection, all three 
of these “lanes” appear to be identical!!  
 
2. Fig. 1E The immunoprecipitation experiment is still not sufficiently described. How was the elution 
performed? How did the authors control for non-specific immunoprecipitation/elution? One good way 
to do this would be to use each of the antibodies against each of the supernatants. Furthermore, it is 
unimpressive to see that the efficiency of the IP is under 10%. I have taken the liberty to graph the 
data without the log representation:  
 
3. The EM results are nice, but the authors should purify the particles by immunoprecipitation rather 
than heparin and should compare particles produced with and without HDV – otherwise, how do we 
know that the particles observed have anything to do with HDV?  
 
4. There are several problems with the description of the strand-specific assay described on lines 497 
– 514. The primers listed are opposite the sense that they should be; that is, the primer 5’- 
CCCGGCTAC…., is genomic sense and would be appropriate for detecting the antigenome, not the 
genome. Likewise for the other primer, which for some reason contains two mismatches to the HDV 
sequence. Moreover, without more information about the RNAs used as standards (presumably they 
are linear), it is not possible to evaluate the strand-specificity. Mis-priming during the RT step on 
circular HDV RNA can decrease strand-specificity in ways that would not be detected using linear RNA 
templates. One might get around this problem by using RNAs of dimer or greater length.  
 
5. The RT-PCR results showing detection of full-length HDV RNA must include controls run without RT. 
Amplification of the full-length HDV RNA by RT-PCR is difficult and this reviewer is not aware of other 
reports to have done so. Although the authors certainly may have succeeded in this task, because 
HDV replication was initiated by transfection of an HDV trimer plasmid DNA, it is possible – even likely 
– that the plasmid was not completely eliminated by the DNase digestion and that the assay is simply 
detecting the HDV plasmid.  
 
6. Is the cytotoxicity really about 40% (Fig. S2A)?? If so, we are all wasting our time.  
 
 
 
Reviewer #2:  
Remarks to the Author:  
The authors have carefully addressed the points that I had raised during the first round of review.  
Please check the manuscript carefully regarding any references of "expressed HDV", e.g. line 240 "As 
control, we performed HBV infection assays in Huh-106 cells expressing HDV". This should be 
corrected throughout.  
 
Congratulations on this very nice, intriguing body of work!  
Reviewers' comments: 
 
Reviewer #1 (Remarks to the Author): 
 
This is a frustrating process. The authors are proposing potentially very interesting and important results. 
Their overall proposal may well fit very nicely with recent observations that viruses closely related to 
HDV exist in other species in the absence of any hepadnavirus (Wille, 2018; Hetzel, 2018 - the authors 
would do well to incorporate this information in their discussion). However, and unfortunately, the 
manuscript still has problems. 
Reply: We feel sorry about this comment. The revision of our work and manuscript was very intense 
and, we believe, allowed incorporation of all the points raised by this Reviewer as well as of most points 
of the other Reviewers. As for the remaining issues, we have done our best to address them in this new 
revised manuscript. 
We have incorporated in the revised Introduction (page 4) the recent observations that viruses closely 
related to HDV exist in other species in the absence of any hepadnavirus, which indeed gives strong 
credit to our observations that HDV can be transmitted by hepadnavirus-unrelated viruses.  
 
 
1. Fig. 1D – the image appears to have been manipulated. The right hand side of the HDV, VSV-∆p and 
HCV-∆p lanes has been cropped in the same manner. Furthermore, on close inspection, all three of 
these “lanes” appear to be identical!! 
Reply: We are humbly asking to accept our most sincere apologies for not having detected the problem 
with this image, which obviously shows that the three lanes (HDV, VSV-∆P, HCV-∆P in our Fig 1D) are 
absolutely identical. After careful examination of the image, it appears that the 4 lanes (i.e., with the 
positive control (Ctrl in Fig 1D)) are the same. We are sorry to say that we have been too quick, owing 
to the intensity of the revision work and we should have been able to immediately detect this absurd 
occurrence. In addition, we are most grateful with this Reviewer for detecting the mistake.  
We truly do not understand what happened. The only bit of explanation that we think about would be a 
bizarre event generated with a Bio-Rad ChemiDoc™ Imager that seems to have replicated part of the 
image (likely part of the Crtl lane). I must say that I have never come across such a situation during my 
career. Actually, we usually use in most of our work (including this study) the Odyssey Imaging System 
from LI-COR Biosciences as it allows linear integration of signals on scales of several logs which is 
essential when dealing with quantifications (see, for example, the Western blot image of Fig 3E that was 
generated with this system). However, because of a breakdown of this equipment that occurred during 
the revision period and of its subsequent repairing time, we had to use a Bio-Rad ChemiDoc™ Imager 
for the image of Fig 1D. We thus believe that either we did not use it properly or, alternatively, that 
something got wrong in the system, but the situation is this one: we were happy when we saw the three 
pairs of bands corresponding to the exact sizes of L-HDAg and S-HDAg, and we did not - and I apologize 
for this - think further than this. 
We feel deeply sorry with the confusion it may have generated, or worse, with the possible opinion of 
this Reviewer who may think that the image would have been manipulated. I am respectfully asking to 
believe that it is certainly not the case and I trust that my professional reputation based on over 30 years 
of academic research in molecular virology confirms my intellectual honesty and that of my team 
colleagues. 
Meanwhile, we have redone this Western blot using the original samples (and processed them with our 
Odyssey Imaging System), which is now displayed in the new revised Figure 1D. 
Once again, please accept our apologies and, above everything, please be convinced of our scientific 
integrity.  
 
 
2. Fig. 1E The immunoprecipitation experiment is still not sufficiently described. How was the elution 
performed? How did the authors control for non-specific immunoprecipitation/elution? One good way to 
do this would be to use each of the antibodies against each of the supernatants. Furthermore, it is 
unimpressive to see that the efficiency of the IP is under 10%. I have taken the liberty to graph the data 
without the log representation: 
Reply: We provide a better description of the method used for this immunoprecipitation experiment in 
our revised manuscript (page 16). To address the concerns of this Reviewer, we now provide the results 
of immunoprecipitation experiments that were controlled as per his/her request, i.e., using each of the 
antibodies against each of the supernatants (new Figure 1e). As also suggested by this Reviewer, we 
now display the data without the log representation. We have also worked to optimize the 
antigen/antibody ratio in order to improve the recovery of HDV particles (now, of over 15%). Yet, we 
propose that the relatively low efficiency of this immunoprecipitation reflects the strong competition by 
HBV, HCV and VSV subviral particles that outnumber the HDV RNA-bearing particles.  
 
 
3. The EM results are nice, but the authors should purify the particles by immunoprecipitation rather 
than heparin and should compare particles produced with and without HDV – otherwise, how do we 
know that the particles observed have anything to do with HDV? 
Reply: We thank this Reviewer for his/her positive appreciation of these EM results that were performed 
as part of our reply to Comment #3 of Reviewer #3 who suggested to provide “a simple EM study (…) 
to visualize the size, distribution of these pseudo-type HDV particles”. Rather, owing to the presence of 
contaminants detected via simple EM studies (data not shown), we undertook a more sophisticated EM 
study of particles purified with heparin beads (Figure 1F and Supplemental Figure 3) with the help of 
the EM facility our campus.  
We respectfully request to this Reviewer that we can keep the EM results as they are in this report for 
the following reasons. Indeed, the purification of the particles by immunoprecipitation with viral surface 
GP antibodies may potentially improve the analysis but would not allow distinguishing HDV particles 
from the subviral particles of either helper virus as they both share the same surface antigen. 
Furthermore, we are concerned that such a study for which we would have to determine and optimize 
many conditions for 3 different viruses investigated simultaneously (HDV, HCV-∆P, VSV-∆P) would 
require a tremendous effort, of largely over a year, and would not provide incremental results relative to 
the set of data in this report. Particularly, from our own experience, eluting antibody-captured particles 
from beads or equivalent material is technically a very difficult issue and also depends on variable 
antigen/antibody affinities between the three virus types. Given the uncertainty of these outcomes, we 
think that this is beyond what is reasonably needed to characterize these novel particles for which we 
believe we have provided multiple and convergent evidence with different biochemical and functional in 
vitro or in vivo assays in this report. Finally, that we did not detect particles when pSVLD3 was expressed 
alone (Figure 1F), that we detected HDV particles in addition to subviral particles when pSVLD3 and 
GP-expression plasmids were co-expressed (Figure 1F and Supplemental Figure 3) but that we only 
detected subviral particles when GP-expression plasmids were individually expressed (Supplemental 
Figure 3) argues that the particles observed are HDV particles.  
 
 
4. There are several problems with the description of the strand-specific assay described on lines 497 
– 514.  
Reply: We thank this Reviewer for inviting us to clarify our methodologies that have been modified in 
the Methods section of our new revised manuscript. The strand-specific RTqPCR method utilized in the 
present study to discriminate and quantify genomic and antigenomic HDV RNA consists in reverse 
transcription reactions with strand-specific primers (opposite polarity as compared to the template) 
followed by qPCR reaction. We addressed below the five concerns of his/her comment. 
 
Concern #1: The primers listed are opposite the sense that they should be; that is, the primer 5’- 
CCCGGCTAC…., is genomic sense and would be appropriate for detecting the antigenome, not the 
genome.  
Reply: We apologize for our sentence “… RNAs were reverse transcribed … using strand-specific 
oligonucleotides primers for genomic RNA 5’-CCGGCTACTCTTCTTTCCCTTCTCTCGTC and for 
antigenomic RNA 5’-CACCGAAGAAGGAAGGCCCTGGAGAACAA” that was unclear. It has been 
replaced by “…, extracted RNAs were reverse transcribed … by using specific primer: genomic primer 
5’-CCGGCTACTCTTCTTTCCCTTCTCTCGTC for genomic-sense cDNA synthesis and antigenomic 
primer 5’-CACCGAAGAAGGAAGGCCCTGGAGAACAA for antigenomic-sense cDNA synthesis” in the 
revised Methods (page 15). 
 
Concern #2: Likewise for the other primer, which for some reason contains two mismatches to the HDV 
sequence.  
Reply: For this primer (5’-CACCGAAGAAGGAAGGCCCTGGAGAACAA), which detects the genomic 
HDV RNA and allows amplification of antigenomic-sense cDNA, its two mismatches to the HDV 
sequence in Genbank M21012 are due to the fact that when we sequenced the pSVLD3 plasmid from 
the EBV-Rev primer (1551-1570 on pSVLD3 Addgene sequence), we detected these mismatches at 
positions 1754 and 1768 in the pSVLD3 Addgene sequence. We therefore decided to synthesize this 
primer in order to best match our sequence and also because the identical primer was used in a previous 
description of the HDV RNA strand-specific RTqPCR assay by Li et al., (2006).  
 
Concern #3: Moreover, without more information about the RNAs used as standards (presumably they 
are linear), it is not possible to evaluate the strand-specificity.  
Reply: We have improved in our revised Methods section the description of the genomic and 
antigenomic HDV RNAs used as standards for this strand-specific RTqPCR assay (page 15). They were 
obtained by in vitro transcription of a set of HDV DNA amplicons flanked by T7 promoters using a 
commercially available kit according to manufacturer’s instructions (RiboMAXTMExpress T7, Promega). 
The full-length linear RNAs were treated with RNase-free-DNase, followed by RNA purification 
(GeneJET RNA purification kit, Thermo Fisher Scientific) and quantified using a Nanodrop device 
(Thermo Fisher Scientific). The genomic or antigenomic HDV RNA calibration standards were diluted in 
RNase-free water and stored at -80°C in single use aliquots. The characterization of genomic and 
antigenomic RNA standards (artificial RNA) with the correct primer and the respective opposite primer 
were performed as described previously by Giersch et al. 2017; Freitas et al 2012; Gudima et al 2007.  
 
Concern #4: Mis-priming during the RT step on circular HDV RNA can decrease strand-specificity in 
ways that would not be detected using linear RNA templates.  
Reply: Mis-priming is defined as non-specific DNA-primer binding and extension during reverse 
transcription. Regarding HDV genomic and antigenomic HDV RNA, since both molecules display high 
degree of intramolecular base pairing it must be considered two types of mispriming: within the same 
molecule (intramolecular mis-priming) or within a molecule of reverse polarity (intermolecular mis-
priming). Strand specific cDNA synthesis was carried out using specifc primers (to minimize RT priming 
at multiple points as with random primers) using a reverse transcriptase with impaired/reduced 
ribonuclease-H activity under a significantly low temperature incubation, two factors shown to reduce 
significantly the potential of template switch events during reverse transcription. Using RNaseH- RTs, 
during elongation of the nascent DNA chain, the RNA template is not degraded and remains as a double 
stranded DNA/RNA molecule of high stability disfavoring the dissociation of the RT from the template. 
In other words, as the nascent cDNA remains complexed to the RNA template, it is unlikely to find and 
bind a different acceptor RNA to allow template switching and production of chimeric cDNAs or cDNAs 
carrying internal deletions.  
The possibility of intermolecular mis-priming was experimentally checked and the results obtained, as 
presented in the Supplemental Figure 1F indicate that intermolecular mis-priming is a very rare event. 
Specifically, it is as low as 0.000001% using 1011 copies of genomic RNA as template and a primer of 
the same polarity and even lower when reverse transcription was carried out using 1011 copies of 
antigenomic HDV RNA as template and a primer of antigenomic polarity, suggesting that in our 
experimental conditions, the primer of genomic polarity almost exclusively detects antigenomic HDV 
RNA and vice-versa.  
Intramolecular mispriming, defined as non-specific binding of the DNA-primer to the same molecule was 
evaluated by assessing the linearity of the reverse transcription step. We foresee that mispriming 
upstream of the specific primer-binding site would not interfere with specific primer binding and 
extension (cDNA synthesis) and quantification by qPCR. The reverse scenario, mispriming downstream 
the specific primer-binding site could have a more important impact, although almost impossible to 
predict, on the kinetics of primer extension and qPCR detection sensitivity. To determine the efficiency 
of RNA-to-cDNA conversion we analyzed the linearity and range of the designed RTqPCR assay. We 
performed cDNA synthesis using a 10-fold serial dilution ranging from 1011 to 10 copies of the in vitro 
synthesized genomic and antigenomic HDV RNA and the results show an efficient and RNA dose-
dependent cDNA synthesis that results in a qPCR standard calibration curve with a slope of -3.3 ± 10% 
reflecting an efficiency close to 100%. It is our opinion that the linearity of the RT reaction over this wide 
range suggests rare intramolecular misprimimg events. We also carefully analyzed the dissociation 
curves of the products obtained from qPCR and there is no indication of any extra subproduct being 
produced other than the expected correct amplicon of less than 100bps with a single dissociation 
temperature. 
 
Concern #5: One might get around this problem by using RNAs of dimer or greater length. 
Reply: Unit length linear HDV RNA standards should closely mimic the circular HDV RNA, the only type 
of HDV RNA molecules incorporated into particles that are secreted from the cells. The major difference 
is that HDV genome inside the particles has no end. Our data strongly suggests that our strand specific 
genomic and antigenomic HDV RNA quantification by RT-qPCR is not significantly biased by inter or 
intramolecular mispriming. We anticipate that the number of mispriming events between a linear and a 
circular RNA molecule of the same size would be similar. Therefore, only one concern remains, strand 
displacement during cDNA synthesis resulting in HDV cDNA concatemers that would led to an over-
estimation of the input RNA by qPCR. Because, RTs have limited processivity (Mohr et al., 2013), this 
consideration is likely to have little effect on large circRNAs (Szabo and Salzman, 2016). For the reasons 
explained above, it is our opinion that there would be no advantage or significant improvement in our 
assays from using dimeric or greater length RNA standards.  
 
Finally, we wish to recall that there is not a standard protocol for quantification of HDV RNA by RTqPCR 
though several groups regularly use one-step RT-qPCR assays (e.g., Ferns et al., 2012; Scholtes et al., 
2012; Karatayli et al., 2014). Likewise for calibration standards, there are no recognized calibration 
standards available for HDV RNA quantification and the quantitative data generated by different 
laboratories are produced by different RTqPCR protocols that use HDV plasmid DNA (Le al., et al 2005; 
Hofmann et al., 2010; Mederacke et al., 2010; Zachou et al., 2010) or in vitro-transcribed genomic or 
antigenomic HDV RNA standards (Freitas et al., 2012; Gudima et al., 2007; Giersch et al., 2017) for 
calibration of assays. Interestingly, despite their differences, these protocols give comparable results for 
the HDV RT-qPCR assays.  
 
 
5. The RT-PCR results showing detection of full-length HDV RNA must include controls run without RT. 
Amplification of the full-length HDV RNA by RT-PCR is difficult and this reviewer is not aware of other 
reports to have done so. Although the authors certainly may have succeeded in this task, because HDV 
replication was initiated by transfection of an HDV trimer plasmid DNA, it is possible – even likely – that 
the plasmid was not completely eliminated by the DNase digestion and that the assay is simply detecting 
the HDV plasmid. 
Reply: We provide in the revised Figure 1B the controls run without RT and/or without DNAse treatment. 
These data indicate that we could detect full-length HDV RNA from replicated RNAs but not from HDV 
trimer plasmid DNA. Please note that the “No GP” control, which does not yield full-length HDV RNA 
detection in the transfected cells supernatants, as well as the detection of full-length HDV RNA in the 
gradient (Figure 1G), in the supernatants of co-infected cells (Figure 6B, F & J) or in the sera of co-
infected animals (Supplemental Figure 7B) also indicate that this method detects replicated and 
secreted HDV RNA. Furthermore, no PCR signal could be detected in the supernatants using a genomic 
primer during the reverse transcription step before PCR amplification, indicating absence of antigenomic 
HDV RNA secretion 
 
6. Is the cytotoxicity really about 40% (Fig. S2A)?? If so, we are all wasting our time. 
Reply: We thank this Reviewer for pointing out this mistake in the display of this Fig. S2A. Indeed, to 
experimentally address the Point #3 of this Reviewer and the Point #2 of Reviewer #2 (“2. In figure 1a, 
the release of virus through cell death should be ruled out.”) of our previous revision, we had tested 
several variations from our HDV production protocol, including production in media with or without 2% 
DMSO, OptiMEM, DMEM+FBS (different FBS doses) and daily change of media vs. 6 day-long 
conditioned media. However, by error, the previous Fig. S2A showed the toxicity results from 
supernatants of cells transfected with the indicated constructs and cultivated using the latter condition, 
i.e., harvested at day 6 post-transfection without daily changing of the media, which we generally do not 
use in our experiments and which raises cytotoxicity levels. 
In our standard conditions (adapted from Ref #29), i.e., for which transfected cells are maintained in a 
daily-changed William’s E medium supplemented with 2% FBS +/- 2% DMSO, the average cytotoxicity 
at day 6 is below 15%, as shown in the revised Fig. S2A, and is similar to that of non-transfected cell 
cultured in parallel. Note that this mistake only concerns Fig. S2A but not the other panels. We have 
corrected this figure in the revised manuscript and we apologize for the inaccuracy.  
 
 
Reviewer #2 (Remarks to the Author): 
 
The authors have carefully addressed the points that I had raised during the first round of review.  
Please check the manuscript carefully regarding any references of "expressed HDV", e.g. line 240 "As 
control, we performed HBV infection assays in Huh-106 cells expressing HDV". This should be corrected 
throughout. 
Reply: We thank this Reviewer for his/her positive appreciation of our revised manuscript and for 
pointing out these sentences that are corrected throughout in the new revised manuscript. 
 
Congratulations on this very nice, intriguing body of work! 
Reply: We thank this Reviewer for his/her nice comment on our study! 
Reviewers' Comments:  
 
Reviewer #1:  
Remarks to the Author:  
The authors have adequately addressed the concerns raised in the prior reviews. The authors' findings 
are very interesting and important for the HDV field, and, as I mentioned in the previous review, 
provide an intriguing fit with recent reports (some published), based on metagenomic analysis, that 
viruses very closely related to HDV exist in other species in the absence of any detectable 
hepadnavirus. 
Reviewers' Comments:  
 
Reviewer #1 (Remarks to the Author):  
The authors have adequately addressed the concerns raised in the prior reviews. The authors' findings 
are very interesting and important for the HDV field, and, as I mentioned in the previous review, 
provide an intriguing fit with recent reports (some published), based on metagenomic analysis, that 
viruses very closely related to HDV exist in other species in the absence of any detectable 
hepadnavirus. 
Reply: We thank this Reviewer for his/her positive appreciation of our revised manuscript and comment 
on our study. 
